Stem definition | Drug id | CAS RN |
---|---|---|
antihyperglycaemics, phenformin derivatives | 1725 | 657-24-9 |
Dose | Unit | Route |
---|---|---|
2 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 99 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 387.10 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 52 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.64 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 7.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 3, 1995 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lactic acidosis | 11686.99 | 9.94 | 5343 | 314268 | 28566 | 46337885 |
Acute kidney injury | 2863.36 | 9.94 | 5487 | 314124 | 230368 | 46136083 |
Hypoglycaemia | 2714.51 | 9.94 | 2538 | 317073 | 51811 | 46314640 |
Blood glucose increased | 2196.49 | 9.94 | 2584 | 317027 | 69429 | 46297022 |
Diabetic ketoacidosis | 2188.69 | 9.94 | 1431 | 318180 | 16779 | 46349672 |
Metabolic acidosis | 1811.55 | 9.94 | 1746 | 317865 | 37034 | 46329417 |
Glycosylated haemoglobin increased | 1020.74 | 9.94 | 734 | 318877 | 10142 | 46356309 |
Ketoacidosis | 1002.95 | 9.94 | 506 | 319105 | 3449 | 46363002 |
Diabetes mellitus inadequate control | 987.30 | 9.94 | 778 | 318833 | 12436 | 46354015 |
Hyperkalaemia | 806.43 | 9.94 | 1331 | 318280 | 49378 | 46317073 |
Hyperglycaemia | 705.21 | 9.94 | 1026 | 318585 | 34045 | 46332406 |
Euglycaemic diabetic ketoacidosis | 653.07 | 9.94 | 305 | 319306 | 1711 | 46364740 |
Rheumatoid arthritis | 580.51 | 9.94 | 476 | 319135 | 239739 | 46126712 |
Hypoglycaemic coma | 476.46 | 9.94 | 267 | 319344 | 2307 | 46364144 |
Pancreatitis | 463.76 | 9.94 | 963 | 318648 | 42664 | 46323787 |
Blood glucose decreased | 455.02 | 9.94 | 603 | 319008 | 18289 | 46348162 |
Pancreatitis acute | 414.37 | 9.94 | 667 | 318944 | 24205 | 46342246 |
Myocardial infarction | 389.41 | 9.94 | 1508 | 318103 | 96020 | 46270431 |
Drug ineffective | 366.45 | 9.94 | 2933 | 316678 | 674905 | 45691546 |
Hyperlactacidaemia | 351.90 | 9.94 | 208 | 319403 | 2007 | 46364444 |
Pemphigoid | 347.36 | 9.94 | 298 | 319313 | 5393 | 46361058 |
Anuria | 344.15 | 9.94 | 408 | 319203 | 11023 | 46355428 |
Shock | 343.83 | 9.94 | 571 | 319040 | 21274 | 46345177 |
Diabetes mellitus | 333.65 | 9.94 | 922 | 318689 | 49143 | 46317308 |
Blood glucose abnormal | 319.90 | 9.94 | 305 | 319306 | 6367 | 46360084 |
Renal failure | 294.90 | 9.94 | 1546 | 318065 | 112048 | 46254403 |
Diarrhoea | 286.83 | 9.94 | 5395 | 314216 | 554207 | 45812244 |
Diabetic metabolic decompensation | 284.11 | 9.94 | 146 | 319465 | 1039 | 46365412 |
Systemic lupus erythematosus | 274.23 | 9.94 | 56 | 319555 | 65124 | 46301327 |
Cardiac failure congestive | 264.30 | 9.94 | 1286 | 318325 | 90464 | 46275987 |
Coronary artery disease | 258.82 | 9.94 | 655 | 318956 | 33097 | 46333354 |
Treatment failure | 256.50 | 9.94 | 160 | 319451 | 92927 | 46273524 |
Drug intolerance | 230.77 | 9.94 | 408 | 319203 | 146641 | 46219810 |
Vomiting | 222.80 | 9.94 | 4340 | 315271 | 448454 | 45917997 |
Haemodialysis | 217.01 | 9.94 | 291 | 319320 | 8926 | 46357525 |
Pancreatic carcinoma | 214.04 | 9.94 | 244 | 319367 | 6313 | 46360138 |
Synovitis | 212.72 | 9.94 | 76 | 319535 | 60999 | 46305452 |
Dehydration | 201.37 | 9.94 | 1818 | 317793 | 157722 | 46208729 |
Hypothermia | 200.54 | 9.94 | 325 | 319286 | 11858 | 46354593 |
Drug level increased | 199.32 | 9.94 | 410 | 319201 | 18031 | 46348420 |
Pemphigus | 188.16 | 9.94 | 40 | 319571 | 45234 | 46321217 |
Off label use | 185.59 | 9.94 | 1685 | 317926 | 378156 | 45988295 |
Febrile neutropenia | 184.10 | 9.94 | 226 | 319385 | 94401 | 46272050 |
Contraindicated product administered | 179.94 | 9.94 | 169 | 319442 | 79778 | 46286673 |
Blood glucose fluctuation | 179.06 | 9.94 | 179 | 319432 | 3967 | 46362484 |
Pyrexia | 175.75 | 9.94 | 1535 | 318076 | 347267 | 46019184 |
Vitamin B12 deficiency | 174.08 | 9.94 | 173 | 319438 | 3806 | 46362645 |
Continuous haemodiafiltration | 164.26 | 9.94 | 97 | 319514 | 934 | 46365517 |
Drug hypersensitivity | 157.57 | 9.94 | 1000 | 318611 | 242825 | 46123626 |
Death | 157.56 | 9.94 | 1503 | 318108 | 334045 | 46032406 |
Infusion related reaction | 154.95 | 9.94 | 285 | 319326 | 100923 | 46265528 |
Neutropenia | 152.31 | 9.94 | 488 | 319123 | 142716 | 46223735 |
Glossodynia | 151.50 | 9.94 | 57 | 319554 | 44316 | 46322135 |
Hand deformity | 151.15 | 9.94 | 27 | 319584 | 34547 | 46331904 |
Rash | 150.86 | 9.94 | 1637 | 317974 | 354875 | 46011576 |
Type 2 diabetes mellitus | 148.50 | 9.94 | 382 | 319229 | 19493 | 46346958 |
Joint swelling | 145.70 | 9.94 | 613 | 318998 | 165460 | 46200991 |
Blood lactic acid increased | 143.07 | 9.94 | 185 | 319426 | 5472 | 46360979 |
Weight decreased | 140.21 | 9.94 | 2123 | 317488 | 208726 | 46157725 |
Pain | 133.82 | 9.94 | 2380 | 317231 | 474568 | 45891883 |
Infection | 130.66 | 9.94 | 472 | 319139 | 133120 | 46233331 |
Rheumatoid factor positive | 125.57 | 9.94 | 3 | 319608 | 20458 | 46345993 |
Cerebrovascular accident | 119.59 | 9.94 | 1136 | 318475 | 99903 | 46266548 |
Musculoskeletal stiffness | 119.44 | 9.94 | 313 | 319298 | 97680 | 46268771 |
Arthropathy | 116.36 | 9.94 | 254 | 319357 | 84446 | 46282005 |
Alopecia | 115.98 | 9.94 | 645 | 318966 | 161769 | 46204682 |
Rhabdomyolysis | 113.18 | 9.94 | 577 | 319034 | 41332 | 46325119 |
Product residue present | 111.01 | 9.94 | 135 | 319476 | 3747 | 46362704 |
Pneumonia | 106.94 | 9.94 | 1873 | 317738 | 374447 | 45992004 |
Acidosis | 101.94 | 9.94 | 232 | 319379 | 10942 | 46355509 |
Blood bicarbonate decreased | 100.39 | 9.94 | 111 | 319500 | 2774 | 46363677 |
Tachypnoea | 93.28 | 9.94 | 262 | 319349 | 14089 | 46352362 |
Hypomagnesaemia | 92.25 | 9.94 | 348 | 319263 | 21862 | 46344589 |
Pancreatic carcinoma metastatic | 91.40 | 9.94 | 97 | 319514 | 2311 | 46364140 |
Hepatic steatosis | 91.15 | 9.94 | 366 | 319245 | 23676 | 46342775 |
Ketosis | 89.70 | 9.94 | 50 | 319561 | 427 | 46366024 |
Injection site nodule | 89.59 | 9.94 | 113 | 319498 | 3258 | 46363193 |
Blood creatinine increased | 88.39 | 9.94 | 855 | 318756 | 75548 | 46290903 |
Fatigue | 86.99 | 9.94 | 3350 | 316261 | 605347 | 45761104 |
Drug interaction | 86.64 | 9.94 | 1908 | 317703 | 201186 | 46165265 |
Swelling | 86.41 | 9.94 | 499 | 319112 | 124012 | 46242439 |
Therapeutic product effect decreased | 84.64 | 9.94 | 286 | 319325 | 82315 | 46284136 |
Urine ketone body present | 84.36 | 9.94 | 88 | 319523 | 2054 | 46364397 |
Hypersensitivity | 82.99 | 9.94 | 645 | 318966 | 149676 | 46216775 |
Toxicity to various agents | 82.73 | 9.94 | 1965 | 317646 | 209801 | 46156650 |
Polyuria | 82.54 | 9.94 | 164 | 319447 | 7031 | 46359420 |
C-reactive protein abnormal | 82.06 | 9.94 | 22 | 319589 | 21248 | 46345203 |
Microalbuminuria | 79.87 | 9.94 | 41 | 319570 | 291 | 46366160 |
Arthralgia | 79.29 | 9.94 | 1896 | 317715 | 362707 | 46003744 |
White blood cell count decreased | 78.83 | 9.94 | 448 | 319163 | 111783 | 46254668 |
Seizure | 75.64 | 9.94 | 512 | 319099 | 122542 | 46243909 |
Intentional overdose | 75.23 | 9.94 | 727 | 318884 | 64217 | 46302234 |
Sinusitis | 72.47 | 9.94 | 555 | 319056 | 129213 | 46237238 |
Disease progression | 72.20 | 9.94 | 350 | 319261 | 90950 | 46275501 |
Diabetic neuropathy | 72.00 | 9.94 | 108 | 319503 | 3681 | 46362770 |
Acetonaemia | 70.77 | 9.94 | 25 | 319586 | 56 | 46366395 |
Acute myocardial infarction | 70.38 | 9.94 | 416 | 319195 | 31508 | 46334943 |
Vasoplegia syndrome | 70.37 | 9.94 | 59 | 319552 | 1033 | 46365418 |
Insulin resistance | 69.90 | 9.94 | 49 | 319562 | 648 | 46365803 |
Cytomegalovirus infection | 69.56 | 9.94 | 19 | 319592 | 18125 | 46348326 |
Postprandial hypoglycaemia | 69.25 | 9.94 | 23 | 319588 | 39 | 46366412 |
Coma acidotic | 68.64 | 9.94 | 28 | 319583 | 106 | 46366345 |
Leukopenia | 68.41 | 9.94 | 239 | 319372 | 68104 | 46298347 |
Neurologic neglect syndrome | 65.96 | 9.94 | 47 | 319564 | 639 | 46365812 |
Ketonuria | 65.58 | 9.94 | 38 | 319573 | 352 | 46366099 |
Hypoglycaemic encephalopathy | 65.58 | 9.94 | 34 | 319577 | 247 | 46366204 |
Thrombocytopenia | 64.88 | 9.94 | 554 | 319057 | 126027 | 46240424 |
Migraine | 64.77 | 9.94 | 253 | 319358 | 69773 | 46296678 |
Pericarditis | 64.67 | 9.94 | 42 | 319569 | 23885 | 46342566 |
Glycosylated haemoglobin decreased | 63.93 | 9.94 | 41 | 319570 | 463 | 46365988 |
Anion gap increased | 63.70 | 9.94 | 64 | 319547 | 1427 | 46365024 |
Carotid artery thrombosis | 63.34 | 9.94 | 47 | 319564 | 683 | 46365768 |
Product use issue | 63.15 | 9.94 | 384 | 319227 | 94260 | 46272191 |
Coronary artery bypass | 61.89 | 9.94 | 80 | 319531 | 2365 | 46364086 |
Lipase increased | 61.84 | 9.94 | 163 | 319448 | 8440 | 46358011 |
Blood ketone body increased | 60 | 9.94 | 32 | 319579 | 248 | 46366203 |
Plasma cell myeloma | 59.73 | 9.94 | 135 | 319476 | 44343 | 46322108 |
Nausea | 59.03 | 9.94 | 5465 | 314146 | 681989 | 45684462 |
Renal impairment | 59.02 | 9.94 | 773 | 318838 | 73599 | 46292852 |
Drug abuse | 58.07 | 9.94 | 230 | 319381 | 63178 | 46303273 |
Adenocarcinoma pancreas | 58.02 | 9.94 | 54 | 319557 | 1092 | 46365359 |
Amylase increased | 56.21 | 9.94 | 119 | 319492 | 5340 | 46361111 |
Angioedema | 56.15 | 9.94 | 461 | 319150 | 38881 | 46327570 |
Wound | 55.80 | 9.94 | 132 | 319479 | 42670 | 46323781 |
Device expulsion | 55.43 | 9.94 | 64 | 319547 | 27478 | 46338973 |
Bone marrow failure | 54.42 | 9.94 | 74 | 319537 | 29595 | 46336856 |
Neutrophil count decreased | 54.19 | 9.94 | 137 | 319474 | 43289 | 46323162 |
Stomatitis | 53.88 | 9.94 | 262 | 319349 | 68035 | 46298416 |
Personality disorder | 53.50 | 9.94 | 85 | 319526 | 3048 | 46363403 |
Diabetic retinopathy | 53.15 | 9.94 | 72 | 319539 | 2230 | 46364221 |
Polydipsia | 51.97 | 9.94 | 86 | 319525 | 3193 | 46363258 |
Arthritis | 51.94 | 9.94 | 313 | 319298 | 77003 | 46289448 |
Drug resistance | 51.89 | 9.94 | 27 | 319584 | 17341 | 46349110 |
Platelet count decreased | 51.58 | 9.94 | 437 | 319174 | 99587 | 46266864 |
Therapeutic product effect incomplete | 51.14 | 9.94 | 319 | 319292 | 77834 | 46288617 |
MELAS syndrome | 50.98 | 9.94 | 22 | 319589 | 99 | 46366352 |
Multiple sclerosis relapse | 50.96 | 9.94 | 135 | 319476 | 41990 | 46324461 |
Angina unstable | 50.23 | 9.94 | 139 | 319472 | 7409 | 46359042 |
Loss of personal independence in daily activities | 50.11 | 9.94 | 211 | 319400 | 56972 | 46309479 |
Peritonitis | 49.95 | 9.94 | 41 | 319570 | 20673 | 46345778 |
Pneumocystis jirovecii pneumonia | 49.72 | 9.94 | 21 | 319590 | 15227 | 46351224 |
Malignant neoplasm progression | 48.97 | 9.94 | 253 | 319358 | 64673 | 46301778 |
Herpes zoster | 48.68 | 9.94 | 269 | 319342 | 67603 | 46298848 |
Infective pulmonary exacerbation of cystic fibrosis | 48.20 | 9.94 | 8 | 319603 | 10799 | 46355652 |
Coronary arterial stent insertion | 48.16 | 9.94 | 77 | 319534 | 2776 | 46363675 |
Headache | 47.98 | 9.94 | 2733 | 316878 | 475619 | 45890832 |
Transplant rejection | 47.82 | 9.94 | 5 | 319606 | 9591 | 46356860 |
Pancreatitis chronic | 46.96 | 9.94 | 60 | 319551 | 1753 | 46364698 |
Injection site erythema | 46.55 | 9.94 | 308 | 319303 | 74119 | 46292332 |
Diabetic nephropathy | 46.51 | 9.94 | 52 | 319559 | 1316 | 46365135 |
Anhidrosis | 46.34 | 9.94 | 20 | 319591 | 90 | 46366361 |
Overdose | 45.95 | 9.94 | 966 | 318645 | 101013 | 46265438 |
Atrioventricular block | 45.89 | 9.94 | 126 | 319485 | 6685 | 46359766 |
Renal tubular necrosis | 45.86 | 9.94 | 170 | 319441 | 10589 | 46355862 |
Hemiplegia | 45.41 | 9.94 | 127 | 319484 | 6811 | 46359640 |
Product odour abnormal | 45.33 | 9.94 | 47 | 319564 | 1089 | 46365362 |
Latent autoimmune diabetes in adults | 45.11 | 9.94 | 13 | 319598 | 9 | 46366442 |
Acute coronary syndrome | 44.98 | 9.94 | 163 | 319448 | 10041 | 46356410 |
Bladder cancer | 44.82 | 9.94 | 77 | 319534 | 2949 | 46363502 |
Hypovolaemic shock | 44.41 | 9.94 | 105 | 319506 | 5078 | 46361373 |
Bone erosion | 44.39 | 9.94 | 6 | 319605 | 9437 | 46357014 |
Drug level above therapeutic | 43.94 | 9.94 | 83 | 319528 | 3426 | 46363025 |
Adjustment disorder | 43.87 | 9.94 | 51 | 319560 | 1348 | 46365103 |
Therapeutic response decreased | 43.76 | 9.94 | 150 | 319461 | 42995 | 46323456 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 43.43 | 9.94 | 33 | 319578 | 498 | 46365953 |
Osteoporosis | 43.38 | 9.94 | 138 | 319473 | 40470 | 46325981 |
Dialysis | 43.25 | 9.94 | 160 | 319451 | 9956 | 46356495 |
Contusion | 42.99 | 9.94 | 387 | 319224 | 87100 | 46279351 |
Cholelithiasis | 42.82 | 9.94 | 429 | 319182 | 38252 | 46328199 |
Anaemia vitamin B12 deficiency | 42.71 | 9.94 | 29 | 319582 | 363 | 46366088 |
C-reactive protein increased | 42.68 | 9.94 | 231 | 319380 | 58359 | 46308092 |
Glomerular filtration rate decreased | 41.93 | 9.94 | 175 | 319436 | 11519 | 46354932 |
Blood potassium increased | 40.60 | 9.94 | 226 | 319385 | 16741 | 46349710 |
Mucosal inflammation | 40.56 | 9.94 | 134 | 319477 | 38842 | 46327609 |
Hospitalisation | 40.30 | 9.94 | 261 | 319350 | 63124 | 46303327 |
Haemophagocytic lymphohistiocytosis | 39.94 | 9.94 | 5 | 319606 | 8337 | 46358114 |
Injection site reaction | 39.83 | 9.94 | 180 | 319431 | 47669 | 46318782 |
Circulatory collapse | 39.72 | 9.94 | 269 | 319342 | 21355 | 46345096 |
Duodenal ulcer perforation | 38.58 | 9.94 | 6 | 319605 | 8496 | 46357955 |
Neurotoxicity | 38.56 | 9.94 | 23 | 319588 | 13694 | 46352757 |
Immune-mediated myositis | 38.55 | 9.94 | 39 | 319572 | 877 | 46365574 |
Cardiac arrest | 38.38 | 9.94 | 849 | 318762 | 89550 | 46276901 |
Glycosylated haemoglobin abnormal | 38.35 | 9.94 | 16 | 319595 | 65 | 46366386 |
Hepatic function abnormal | 38.17 | 9.94 | 115 | 319496 | 34306 | 46332145 |
Blood triglycerides increased | 38.16 | 9.94 | 171 | 319440 | 11612 | 46354839 |
Maternal exposure during pregnancy | 38.11 | 9.94 | 484 | 319127 | 102065 | 46264386 |
Pain in jaw | 37.85 | 9.94 | 135 | 319476 | 38237 | 46328214 |
Systemic infection | 37.79 | 9.94 | 34 | 319577 | 657 | 46365794 |
Tenosynovitis | 37.23 | 9.94 | 4 | 319607 | 7511 | 46358940 |
Peripheral swelling | 37.05 | 9.94 | 812 | 318799 | 157259 | 46209192 |
Nasopharyngitis | 36.99 | 9.94 | 788 | 318823 | 153210 | 46213241 |
Heart injury | 36.92 | 9.94 | 44 | 319567 | 1195 | 46365256 |
Tubulointerstitial nephritis | 36.74 | 9.94 | 199 | 319412 | 14589 | 46351862 |
Electrocardiogram T wave peaked | 36.47 | 9.94 | 21 | 319590 | 192 | 46366259 |
Diabetic ketosis | 36.46 | 9.94 | 20 | 319591 | 165 | 46366286 |
Exposure during pregnancy | 36.24 | 9.94 | 984 | 318627 | 107228 | 46259223 |
Haematotoxicity | 36.18 | 9.94 | 3 | 319608 | 6930 | 46359521 |
Device related infection | 36.10 | 9.94 | 55 | 319556 | 20986 | 46345465 |
Urine albumin/creatinine ratio abnormal | 35.92 | 9.94 | 9 | 319602 | 0 | 46366451 |
Colitis ulcerative | 35.90 | 9.94 | 41 | 319570 | 17691 | 46348760 |
Product complaint | 35.78 | 9.94 | 171 | 319440 | 11930 | 46354521 |
Rheumatoid nodule | 35.42 | 9.94 | 9 | 319602 | 9011 | 46357440 |
Abdominal discomfort | 35.29 | 9.94 | 777 | 318834 | 150388 | 46216063 |
Posterior reversible encephalopathy syndrome | 35.24 | 9.94 | 31 | 319580 | 15110 | 46351341 |
Gastroenteritis | 34.13 | 9.94 | 283 | 319328 | 23936 | 46342515 |
Persistent cloaca | 33.83 | 9.94 | 20 | 319591 | 193 | 46366258 |
Kussmaul respiration | 33.59 | 9.94 | 18 | 319593 | 141 | 46366310 |
Transient ischaemic attack | 33.44 | 9.94 | 376 | 319235 | 34527 | 46331924 |
Febrile bone marrow aplasia | 33.13 | 9.94 | 4 | 319607 | 6858 | 46359593 |
Diabetic ketoacidotic hyperglycaemic coma | 32.97 | 9.94 | 14 | 319597 | 60 | 46366391 |
Multiple sclerosis | 32.67 | 9.94 | 76 | 319535 | 24715 | 46341736 |
Toothache | 32.65 | 9.94 | 210 | 319401 | 16382 | 46350069 |
Bradycardia | 32.50 | 9.94 | 636 | 318975 | 65662 | 46300789 |
Oliguria | 32.13 | 9.94 | 132 | 319479 | 8627 | 46357824 |
Therapy non-responder | 31.80 | 9.94 | 159 | 319452 | 40993 | 46325458 |
Ischaemic cardiomyopathy | 31.77 | 9.94 | 61 | 319550 | 2549 | 46363902 |
Erythema | 31.67 | 9.94 | 740 | 318871 | 142080 | 46224371 |
Left ventricular hypertrophy | 31.65 | 9.94 | 90 | 319521 | 4873 | 46361578 |
Osteonecrosis of jaw | 31.35 | 9.94 | 125 | 319486 | 34277 | 46332174 |
Cerebral venous thrombosis | 31.34 | 9.94 | 54 | 319557 | 2073 | 46364378 |
Confusional state | 31.28 | 9.94 | 1366 | 318245 | 158526 | 46207925 |
Insulin C-peptide decreased | 31.25 | 9.94 | 10 | 319601 | 14 | 46366437 |
Device dislocation | 31.07 | 9.94 | 64 | 319547 | 21738 | 46344713 |
Stevens-Johnson syndrome | 31.04 | 9.94 | 71 | 319540 | 23226 | 46343225 |
Diabetic ulcer | 30.59 | 9.94 | 19 | 319592 | 202 | 46366249 |
Fluid overload | 30.01 | 9.94 | 91 | 319520 | 27094 | 46339357 |
Oedematous pancreatitis | 29.74 | 9.94 | 22 | 319589 | 318 | 46366133 |
High density lipoprotein decreased | 29.71 | 9.94 | 48 | 319563 | 1746 | 46364705 |
Blood creatine phosphokinase increased | 29.50 | 9.94 | 305 | 319306 | 27419 | 46339032 |
Haemofiltration | 29.40 | 9.94 | 8 | 319603 | 3 | 46366448 |
Body mass index increased | 29.35 | 9.94 | 36 | 319575 | 1008 | 46365443 |
Myocardial ischaemia | 29.31 | 9.94 | 168 | 319443 | 12581 | 46353870 |
Intestinal malrotation | 29.23 | 9.94 | 22 | 319589 | 327 | 46366124 |
Progressive multifocal leukoencephalopathy | 29.21 | 9.94 | 21 | 319590 | 11325 | 46355126 |
Clostridium difficile infection | 29.19 | 9.94 | 82 | 319529 | 25021 | 46341430 |
Immunodeficiency | 29.12 | 9.94 | 28 | 319583 | 13078 | 46353373 |
Haemodynamic instability | 28.80 | 9.94 | 117 | 319494 | 7608 | 46358843 |
Foreign body aspiration | 28.67 | 9.94 | 17 | 319594 | 165 | 46366286 |
Status epilepticus | 28.65 | 9.94 | 32 | 319579 | 13947 | 46352504 |
Constipation | 28.58 | 9.94 | 941 | 318670 | 173156 | 46193295 |
Psoriasis | 28.40 | 9.94 | 722 | 318889 | 77882 | 46288569 |
Pancreatic mass | 28.40 | 9.94 | 32 | 319579 | 817 | 46365634 |
Musculoskeletal pain | 28.33 | 9.94 | 325 | 319286 | 69803 | 46296648 |
Fungal infection | 28.27 | 9.94 | 318 | 319293 | 29202 | 46337249 |
Mouth ulceration | 28.09 | 9.94 | 92 | 319519 | 26740 | 46339711 |
Genital infection fungal | 28.08 | 9.94 | 17 | 319594 | 172 | 46366279 |
Suicide attempt | 28.01 | 9.94 | 531 | 319080 | 54505 | 46311946 |
Cholecystitis chronic | 27.95 | 9.94 | 144 | 319467 | 10355 | 46356096 |
Myelosuppression | 27.83 | 9.94 | 9 | 319602 | 7694 | 46358757 |
Bursitis | 27.65 | 9.94 | 59 | 319552 | 19783 | 46346668 |
Anaemia macrocytic | 27.51 | 9.94 | 58 | 319553 | 2595 | 46363856 |
Blood insulin decreased | 27.49 | 9.94 | 8 | 319603 | 6 | 46366445 |
Bladder sphincter atony | 27.36 | 9.94 | 16 | 319595 | 151 | 46366300 |
Prerenal failure | 27.36 | 9.94 | 41 | 319570 | 1396 | 46365055 |
Anaemia megaloblastic | 27.25 | 9.94 | 21 | 319590 | 324 | 46366127 |
Condition aggravated | 27.09 | 9.94 | 1386 | 318225 | 243666 | 46122785 |
Inflammation | 27.03 | 9.94 | 209 | 319402 | 48572 | 46317879 |
Vitamin B12 decreased | 26.86 | 9.94 | 59 | 319552 | 2716 | 46363735 |
Aspergillus infection | 26.82 | 9.94 | 7 | 319604 | 6883 | 46359568 |
Mobility decreased | 26.81 | 9.94 | 275 | 319336 | 60319 | 46306132 |
Hypotension | 26.55 | 9.94 | 1891 | 317720 | 230698 | 46135753 |
Osteonecrosis | 26.45 | 9.94 | 89 | 319522 | 25655 | 46340796 |
Metabolic syndrome | 26.42 | 9.94 | 38 | 319573 | 1246 | 46365205 |
Blood lactic acid | 26.41 | 9.94 | 14 | 319597 | 107 | 46366344 |
Pulmonary arterial hypertension | 26.39 | 9.94 | 90 | 319521 | 25838 | 46340613 |
Lymphopenia | 26.22 | 9.94 | 40 | 319571 | 15253 | 46351198 |
Pharyngitis | 26.15 | 9.94 | 208 | 319403 | 17375 | 46349076 |
Renal abscess | 26.10 | 9.94 | 27 | 319584 | 624 | 46365827 |
IIIrd nerve paresis | 26.08 | 9.94 | 13 | 319598 | 86 | 46366365 |
Immune reconstitution inflammatory syndrome | 26.07 | 9.94 | 4 | 319607 | 5721 | 46360730 |
Hip arthroplasty | 25.96 | 9.94 | 53 | 319558 | 18059 | 46348392 |
Lymphocyte count decreased | 25.92 | 9.94 | 89 | 319522 | 25500 | 46340951 |
Angina pectoris | 25.90 | 9.94 | 289 | 319322 | 26486 | 46339965 |
Albuminuria | 25.64 | 9.94 | 17 | 319594 | 204 | 46366247 |
Blood pH decreased | 25.59 | 9.94 | 56 | 319555 | 2571 | 46363880 |
Pleural effusion | 25.35 | 9.94 | 407 | 319204 | 82545 | 46283906 |
Bone density decreased | 25.17 | 9.94 | 18 | 319593 | 9734 | 46356717 |
Impaired healing | 25.06 | 9.94 | 148 | 319463 | 36595 | 46329856 |
Product use in unapproved indication | 24.97 | 9.94 | 451 | 319160 | 89822 | 46276629 |
Thrombotic microangiopathy | 24.68 | 9.94 | 13 | 319598 | 8293 | 46358158 |
Osmolar gap | 24.67 | 9.94 | 13 | 319598 | 98 | 46366353 |
Acute myeloid leukaemia | 24.51 | 9.94 | 44 | 319567 | 15734 | 46350717 |
Diabetic foot | 24.45 | 9.94 | 42 | 319569 | 1608 | 46364843 |
Discomfort | 24.45 | 9.94 | 203 | 319408 | 46467 | 46319984 |
Generalised tonic-clonic seizure | 24.43 | 9.94 | 99 | 319512 | 27023 | 46339428 |
Epstein-Barr virus infection | 24.38 | 9.94 | 8 | 319603 | 6776 | 46359675 |
Diabetic hyperosmolar coma | 24.33 | 9.94 | 22 | 319589 | 428 | 46366023 |
Allergic reaction to excipient | 24.29 | 9.94 | 19 | 319592 | 300 | 46366151 |
Conjoined twins | 24.17 | 9.94 | 18 | 319593 | 263 | 46366188 |
Creatinine renal clearance abnormal | 24.06 | 9.94 | 16 | 319595 | 193 | 46366258 |
Complication associated with device | 24.04 | 9.94 | 43 | 319568 | 15398 | 46351053 |
Shock hypoglycaemic | 23.93 | 9.94 | 13 | 319598 | 105 | 46366346 |
Staphylococcal infection | 23.91 | 9.94 | 145 | 319466 | 35626 | 46330825 |
Pathogen resistance | 23.89 | 9.94 | 6 | 319605 | 6054 | 46360397 |
Cleft lip | 23.52 | 9.94 | 13 | 319598 | 109 | 46366342 |
Chills | 23.45 | 9.94 | 490 | 319121 | 95542 | 46270909 |
Bronchopulmonary aspergillosis | 23.38 | 9.94 | 11 | 319600 | 7485 | 46358966 |
Macular oedema | 22.95 | 9.94 | 71 | 319540 | 4030 | 46362421 |
Dry eye | 22.94 | 9.94 | 118 | 319493 | 30204 | 46336247 |
Temperature perception test abnormal | 22.93 | 9.94 | 8 | 319603 | 17 | 46366434 |
Oral herpes | 22.80 | 9.94 | 63 | 319548 | 19327 | 46347124 |
Unevaluable event | 22.79 | 9.94 | 204 | 319407 | 45971 | 46320480 |
Obesity | 22.76 | 9.94 | 171 | 319440 | 14035 | 46352416 |
Abdominal pain | 22.72 | 9.94 | 1849 | 317762 | 228182 | 46138269 |
Pruritus genital | 22.70 | 9.94 | 25 | 319586 | 622 | 46365829 |
Pregnancy | 22.63 | 9.94 | 102 | 319509 | 27035 | 46339416 |
Pyelonephritis acute | 22.61 | 9.94 | 71 | 319540 | 4063 | 46362388 |
Thalamic infarction | 22.56 | 9.94 | 23 | 319588 | 522 | 46365929 |
Cold sweat | 22.45 | 9.94 | 140 | 319471 | 10805 | 46355646 |
Drug dependence | 22.41 | 9.94 | 66 | 319545 | 19835 | 46346616 |
Gait inability | 22.37 | 9.94 | 352 | 319259 | 34851 | 46331600 |
Basal cell carcinoma | 22.32 | 9.94 | 69 | 319542 | 20418 | 46346033 |
Ischaemic stroke | 22.29 | 9.94 | 193 | 319418 | 16529 | 46349922 |
Oxygen saturation decreased | 22.27 | 9.94 | 336 | 319275 | 68828 | 46297623 |
Red blood cell sedimentation rate increased | 22.26 | 9.94 | 81 | 319530 | 22808 | 46343643 |
Foot deformity | 22.22 | 9.94 | 45 | 319566 | 15380 | 46351071 |
Blindness transient | 22.10 | 9.94 | 61 | 319550 | 3246 | 46363205 |
Blood growth hormone increased | 22.00 | 9.94 | 20 | 319591 | 392 | 46366059 |
Enthesopathy | 22.00 | 9.94 | 3 | 319608 | 4687 | 46361764 |
Sopor | 21.99 | 9.94 | 220 | 319391 | 19608 | 46346843 |
Glucose urine present | 21.92 | 9.94 | 25 | 319586 | 647 | 46365804 |
Urine albumin/creatinine ratio increased | 21.91 | 9.94 | 14 | 319597 | 157 | 46366294 |
Oropharyngeal pain | 21.64 | 9.94 | 367 | 319244 | 73801 | 46292650 |
Stool analysis abnormal | 21.57 | 9.94 | 10 | 319601 | 55 | 46366396 |
Glomerular filtration rate abnormal | 21.56 | 9.94 | 22 | 319589 | 500 | 46365951 |
Product prescribing error | 21.54 | 9.94 | 221 | 319390 | 19826 | 46346625 |
Anovulatory cycle | 21.43 | 9.94 | 13 | 319598 | 132 | 46366319 |
Hypoglycaemic unconsciousness | 21.42 | 9.94 | 26 | 319585 | 720 | 46365731 |
Injection site swelling | 21.31 | 9.94 | 175 | 319436 | 40152 | 46326299 |
Pancreatic atrophy | 21.28 | 9.94 | 12 | 319599 | 105 | 46366346 |
Clostridium difficile colitis | 21.28 | 9.94 | 61 | 319550 | 18492 | 46347959 |
Exposure via ingestion | 21.27 | 9.94 | 62 | 319549 | 3405 | 46363046 |
Unintentional medical device removal | 21.15 | 9.94 | 3 | 319608 | 4550 | 46361901 |
Flushing | 21.11 | 9.94 | 313 | 319298 | 64301 | 46302150 |
Intestinal perforation | 20.99 | 9.94 | 26 | 319585 | 10825 | 46355626 |
Base excess negative | 20.91 | 9.94 | 6 | 319605 | 4 | 46366447 |
Bronchostenosis | 20.83 | 9.94 | 18 | 319593 | 329 | 46366122 |
Decreased appetite | 20.76 | 9.94 | 1568 | 318043 | 192268 | 46174183 |
Dyslipidaemia | 20.72 | 9.94 | 84 | 319527 | 5456 | 46360995 |
Body temperature decreased | 20.70 | 9.94 | 160 | 319451 | 13249 | 46353202 |
Cytomegalovirus viraemia | 20.69 | 9.94 | 3 | 319608 | 4475 | 46361976 |
Endometrial adenocarcinoma | 20.60 | 9.94 | 32 | 319579 | 1125 | 46365326 |
Hyperinsulinaemic hypoglycaemia | 20.43 | 9.94 | 9 | 319602 | 43 | 46366408 |
Overweight | 20.39 | 9.94 | 57 | 319554 | 3056 | 46363395 |
Product substitution issue | 20.31 | 9.94 | 174 | 319437 | 14857 | 46351594 |
Nephrogenic systemic fibrosis | 20.27 | 9.94 | 4 | 319607 | 4768 | 46361683 |
Jaundice hepatocellular | 20.09 | 9.94 | 8 | 319603 | 28 | 46366423 |
Mitochondrial enzyme deficiency | 20.09 | 9.94 | 8 | 319603 | 28 | 46366423 |
Pneumothorax | 19.97 | 9.94 | 44 | 319567 | 14585 | 46351866 |
Hepatosplenomegaly neonatal | 19.96 | 9.94 | 5 | 319606 | 0 | 46366451 |
Multiple cardiac defects | 19.96 | 9.94 | 5 | 319606 | 0 | 46366451 |
Mechanical ventilation complication | 19.96 | 9.94 | 5 | 319606 | 0 | 46366451 |
Premature labour | 19.91 | 9.94 | 29 | 319582 | 11270 | 46355181 |
Thirst | 19.83 | 9.94 | 136 | 319475 | 10840 | 46355611 |
Peritonitis bacterial | 19.80 | 9.94 | 18 | 319593 | 8635 | 46357816 |
Carcinoid tumour of the stomach | 19.75 | 9.94 | 13 | 319598 | 154 | 46366297 |
CD30 expression | 19.67 | 9.94 | 8 | 319603 | 30 | 46366421 |
Pancreaticoduodenectomy | 19.67 | 9.94 | 8 | 319603 | 30 | 46366421 |
Disease recurrence | 19.56 | 9.94 | 63 | 319548 | 18408 | 46348043 |
Apolipoprotein A-I decreased | 19.47 | 9.94 | 8 | 319603 | 31 | 46366420 |
Oxygen saturation immeasurable | 19.35 | 9.94 | 6 | 319605 | 7 | 46366444 |
Femur fracture | 19.35 | 9.94 | 161 | 319450 | 36836 | 46329615 |
Dysentery | 19.32 | 9.94 | 25 | 319586 | 740 | 46365711 |
Necrotising myositis | 19.30 | 9.94 | 17 | 319594 | 319 | 46366132 |
Accidental overdose | 19.14 | 9.94 | 216 | 319395 | 19850 | 46346601 |
Cough | 19.08 | 9.94 | 1338 | 318273 | 228911 | 46137540 |
Accidental exposure to product | 18.95 | 9.94 | 77 | 319534 | 21004 | 46345447 |
Hyperinsulinaemia | 18.91 | 9.94 | 10 | 319601 | 76 | 46366375 |
Soft tissue disorder | 18.89 | 9.94 | 3 | 319608 | 4183 | 46362268 |
Osmolar gap increased | 18.88 | 9.94 | 7 | 319604 | 19 | 46366432 |
Suicidal ideation | 18.81 | 9.94 | 272 | 319339 | 56110 | 46310341 |
Hyperhidrosis | 18.80 | 9.94 | 769 | 318842 | 88539 | 46277912 |
Ascites | 18.77 | 9.94 | 160 | 319451 | 36424 | 46330027 |
Nonalcoholic fatty liver disease | 18.71 | 9.94 | 25 | 319586 | 764 | 46365687 |
Upper respiratory tract infection | 18.70 | 9.94 | 314 | 319297 | 63242 | 46303209 |
Body temperature increased | 18.67 | 9.94 | 97 | 319514 | 24764 | 46341687 |
Musculoskeletal disorder | 18.66 | 9.94 | 50 | 319561 | 15495 | 46350956 |
Hepatic cirrhosis | 18.64 | 9.94 | 177 | 319434 | 15555 | 46350896 |
Skin ulcer | 18.48 | 9.94 | 138 | 319473 | 32320 | 46334131 |
Colitis | 18.43 | 9.94 | 165 | 319446 | 37182 | 46329269 |
Neck pain | 18.38 | 9.94 | 267 | 319344 | 55039 | 46311412 |
Intentional self-injury | 18.31 | 9.94 | 94 | 319517 | 24072 | 46342379 |
Lymphadenopathy | 18.30 | 9.94 | 144 | 319467 | 33344 | 46333107 |
Adrenal adenoma | 18.27 | 9.94 | 26 | 319585 | 844 | 46365607 |
Congenital bladder anomaly | 18.17 | 9.94 | 13 | 319598 | 178 | 46366273 |
Hypovolaemia | 18.15 | 9.94 | 123 | 319488 | 9765 | 46356686 |
Cytokine release syndrome | 18.11 | 9.94 | 10 | 319601 | 6213 | 46360238 |
Multiple organ dysfunction syndrome | 18.10 | 9.94 | 473 | 319138 | 51237 | 46315214 |
Diffuse large B-cell lymphoma | 18.08 | 9.94 | 9 | 319602 | 5929 | 46360522 |
Urachal abnormality | 17.92 | 9.94 | 13 | 319598 | 182 | 46366269 |
Bone pain | 17.90 | 9.94 | 220 | 319391 | 46670 | 46319781 |
Blood ketone body | 17.87 | 9.94 | 8 | 319603 | 40 | 46366411 |
Blood phosphorus increased | 17.86 | 9.94 | 51 | 319560 | 2768 | 46363683 |
Product blister packaging issue | 17.75 | 9.94 | 13 | 319598 | 185 | 46366266 |
Congenital absence of bile ducts | 17.71 | 9.94 | 8 | 319603 | 41 | 46366410 |
Hypertensive heart disease | 17.68 | 9.94 | 48 | 319563 | 2530 | 46363921 |
Hyperphagia | 17.67 | 9.94 | 36 | 319575 | 1572 | 46364879 |
Catheter site erythema | 17.65 | 9.94 | 3 | 319608 | 3980 | 46362471 |
Insulin resistant diabetes | 17.63 | 9.94 | 5 | 319606 | 3 | 46366448 |
Unresponsive to stimuli | 17.61 | 9.94 | 314 | 319297 | 31860 | 46334591 |
Metastases to retroperitoneum | 17.55 | 9.94 | 12 | 319599 | 152 | 46366299 |
Agranulocytosis | 17.55 | 9.94 | 85 | 319526 | 22100 | 46344351 |
Pancreatic failure | 17.54 | 9.94 | 21 | 319590 | 573 | 46365878 |
Hypoparathyroidism | 17.53 | 9.94 | 22 | 319589 | 631 | 46365820 |
Non-alcoholic steatohepatitis | 17.43 | 9.94 | 34 | 319577 | 1438 | 46365013 |
Medication error | 17.39 | 9.94 | 303 | 319308 | 30608 | 46335843 |
Diabetic complication | 17.37 | 9.94 | 27 | 319584 | 950 | 46365501 |
Serotonin syndrome | 17.35 | 9.94 | 96 | 319515 | 24124 | 46342327 |
Optic neuritis | 17.32 | 9.94 | 13 | 319598 | 6858 | 46359593 |
Congenital aortic valve stenosis | 17.29 | 9.94 | 9 | 319602 | 66 | 46366385 |
Bundle branch block left | 17.19 | 9.94 | 88 | 319523 | 6311 | 46360140 |
Pelvic fracture | 17.19 | 9.94 | 33 | 319578 | 11506 | 46354945 |
Abdominal pain upper | 17.19 | 9.94 | 1185 | 318426 | 144120 | 46222331 |
Autoimmune myositis | 17.18 | 9.94 | 9 | 319602 | 67 | 46366384 |
Brain stem infarction | 17.15 | 9.94 | 25 | 319586 | 830 | 46365621 |
Pulmonary fibrosis | 17.07 | 9.94 | 75 | 319536 | 20017 | 46346434 |
Tinnitus | 17.05 | 9.94 | 115 | 319496 | 27558 | 46338893 |
Creatinine renal clearance | 17.04 | 9.94 | 5 | 319606 | 4 | 46366447 |
Glycosylated haemoglobin | 17.04 | 9.94 | 5 | 319606 | 4 | 46366447 |
Dyskinesia | 16.94 | 9.94 | 122 | 319489 | 28803 | 46337648 |
Eating disorder | 16.93 | 9.94 | 164 | 319447 | 14490 | 46351961 |
Accidental underdose | 16.88 | 9.94 | 21 | 319590 | 597 | 46365854 |
Knee arthroplasty | 16.85 | 9.94 | 94 | 319517 | 23571 | 46342880 |
Cervix neoplasm | 16.79 | 9.94 | 13 | 319598 | 202 | 46366249 |
Affect lability | 16.71 | 9.94 | 103 | 319508 | 7917 | 46358534 |
Neuropathy, ataxia, retinitis pigmentosa syndrome | 16.69 | 9.94 | 8 | 319603 | 48 | 46366403 |
Ankylosing spondylitis | 16.66 | 9.94 | 13 | 319598 | 6724 | 46359727 |
Blood pressure inadequately controlled | 16.64 | 9.94 | 67 | 319544 | 4339 | 46362112 |
Lung disorder | 16.60 | 9.94 | 203 | 319408 | 43101 | 46323350 |
Basilar artery thrombosis | 16.59 | 9.94 | 11 | 319600 | 132 | 46366319 |
Tuberculosis | 16.51 | 9.94 | 28 | 319583 | 10237 | 46356214 |
Paraesthesia | 16.47 | 9.94 | 647 | 318964 | 116790 | 46249661 |
Pancreatic enzymes increased | 16.45 | 9.94 | 22 | 319589 | 673 | 46365778 |
Prothrombin consumption time prolonged | 16.42 | 9.94 | 8 | 319603 | 50 | 46366401 |
Hunger | 16.32 | 9.94 | 61 | 319550 | 3814 | 46362637 |
Vulvovaginal mycotic infection | 16.30 | 9.94 | 66 | 319545 | 4285 | 46362166 |
Pulseless electrical activity | 16.18 | 9.94 | 94 | 319517 | 7073 | 46359378 |
Prescription drug used without a prescription | 16.13 | 9.94 | 32 | 319579 | 1370 | 46365081 |
Blood insulin increased | 16.13 | 9.94 | 10 | 319601 | 106 | 46366345 |
Completed suicide | 16.05 | 9.94 | 1183 | 318428 | 144737 | 46221714 |
Skinfold measurement | 15.96 | 9.94 | 4 | 319607 | 0 | 46366451 |
Hyperfibrinogenaemia | 15.96 | 9.94 | 4 | 319607 | 0 | 46366451 |
Ectopia cordis | 15.96 | 9.94 | 4 | 319607 | 0 | 46366451 |
Pleural mesothelioma | 15.96 | 9.94 | 4 | 319607 | 0 | 46366451 |
Blood lactate dehydrogenase increased | 15.95 | 9.94 | 79 | 319532 | 20421 | 46346030 |
Incorrect route of product administration | 15.91 | 9.94 | 58 | 319553 | 16325 | 46350126 |
Cystic fibrosis | 15.86 | 9.94 | 3 | 319608 | 3685 | 46362766 |
Monoclonal B-cell lymphocytosis | 15.80 | 9.94 | 7 | 319604 | 34 | 46366417 |
Differential white blood cell count abnormal | 15.66 | 9.94 | 21 | 319590 | 644 | 46365807 |
Coronary artery occlusion | 15.61 | 9.94 | 102 | 319509 | 8000 | 46358451 |
Therapeutic drug monitoring analysis not performed | 15.60 | 9.94 | 18 | 319593 | 472 | 46365979 |
Joint stiffness | 15.55 | 9.94 | 115 | 319496 | 26993 | 46339458 |
Transfusion | 15.55 | 9.94 | 43 | 319568 | 13188 | 46353263 |
Congenital uterine anomaly | 15.51 | 9.94 | 10 | 319601 | 114 | 46366337 |
Medullary thyroid cancer | 15.51 | 9.94 | 10 | 319601 | 114 | 46366337 |
Pancreatectomy | 15.51 | 9.94 | 6 | 319605 | 19 | 46366432 |
Flatulence | 15.51 | 9.94 | 281 | 319330 | 28597 | 46337854 |
Bicuspid aortic valve | 15.51 | 9.94 | 10 | 319601 | 114 | 46366337 |
Arteriosclerosis | 15.51 | 9.94 | 117 | 319494 | 9616 | 46356835 |
Haemoglobin decreased | 15.46 | 9.94 | 723 | 318888 | 128226 | 46238225 |
Dyspnoea | 15.36 | 9.94 | 3207 | 316404 | 512341 | 45854110 |
Eyelid bleeding | 15.32 | 9.94 | 7 | 319604 | 37 | 46366414 |
Injection site bruising | 15.24 | 9.94 | 163 | 319448 | 35473 | 46330978 |
Macrosomia | 15.22 | 9.94 | 8 | 319603 | 60 | 46366391 |
Disability | 15.22 | 9.94 | 29 | 319582 | 10138 | 46356313 |
Pulmonary hypoplasia | 15.21 | 9.94 | 14 | 319597 | 279 | 46366172 |
Bone disorder | 15.13 | 9.94 | 78 | 319533 | 19955 | 46346496 |
Metastases to kidney | 15.05 | 9.94 | 12 | 319599 | 195 | 46366256 |
Pancreatic carcinoma stage IV | 15.03 | 9.94 | 7 | 319604 | 39 | 46366412 |
Anion gap abnormal | 15.02 | 9.94 | 15 | 319596 | 332 | 46366119 |
Cutaneous T-cell dyscrasia | 15 | 9.94 | 8 | 319603 | 62 | 46366389 |
Pneumonia aspiration | 15.00 | 9.94 | 141 | 319470 | 31464 | 46334987 |
Device issue | 14.98 | 9.94 | 78 | 319533 | 19902 | 46346549 |
Night sweats | 14.98 | 9.94 | 117 | 319494 | 27133 | 46339318 |
Respiratory tract infection | 14.97 | 9.94 | 132 | 319479 | 29840 | 46336611 |
Blood pressure systolic decreased | 14.90 | 9.94 | 74 | 319537 | 5244 | 46361207 |
Large intestine perforation | 14.84 | 9.94 | 18 | 319593 | 7562 | 46358889 |
Glucose tolerance impaired | 14.82 | 9.94 | 69 | 319542 | 4762 | 46361689 |
Intestinal obstruction | 14.78 | 9.94 | 111 | 319500 | 25964 | 46340487 |
Epileptic encephalopathy | 14.76 | 9.94 | 13 | 319598 | 244 | 46366207 |
Ulcer | 14.73 | 9.94 | 65 | 319546 | 17327 | 46349124 |
Resuscitation | 14.67 | 9.94 | 27 | 319584 | 1092 | 46365359 |
Hyponatraemic encephalopathy | 14.67 | 9.94 | 13 | 319598 | 246 | 46366205 |
Device difficult to use | 14.64 | 9.94 | 20 | 319591 | 7984 | 46358467 |
Insulin-like growth factor increased | 14.64 | 9.94 | 22 | 319589 | 751 | 46365700 |
Thyroglobulin increased | 14.60 | 9.94 | 7 | 319604 | 42 | 46366409 |
Renal tubular acidosis | 14.58 | 9.94 | 33 | 319578 | 1550 | 46364901 |
Liver disorder | 14.50 | 9.94 | 174 | 319437 | 37072 | 46329379 |
Myxoedema coma | 14.50 | 9.94 | 16 | 319595 | 399 | 46366052 |
Sleep disorder due to general medical condition, insomnia type | 14.48 | 9.94 | 9 | 319602 | 5240 | 46361211 |
Persistent left superior vena cava | 14.47 | 9.94 | 7 | 319604 | 43 | 46366408 |
Irritable bowel syndrome | 14.43 | 9.94 | 61 | 319550 | 16454 | 46349997 |
Genital swelling | 14.41 | 9.94 | 10 | 319601 | 130 | 46366321 |
Ill-defined disorder | 14.36 | 9.94 | 116 | 319495 | 26711 | 46339740 |
Needle issue | 14.35 | 9.94 | 78 | 319533 | 5726 | 46360725 |
Herpes simplex | 14.30 | 9.94 | 17 | 319594 | 7206 | 46359245 |
Myopathy | 14.29 | 9.94 | 107 | 319504 | 8774 | 46357677 |
Blood electrolytes abnormal | 14.25 | 9.94 | 25 | 319586 | 974 | 46365477 |
Cardiotoxicity | 14.21 | 9.94 | 15 | 319596 | 6707 | 46359744 |
Glycosuria | 14.12 | 9.94 | 26 | 319585 | 1052 | 46365399 |
Scleroderma | 14.12 | 9.94 | 7 | 319604 | 4622 | 46361829 |
Panniculitis | 14.11 | 9.94 | 11 | 319600 | 5693 | 46360758 |
Drug withdrawal syndrome | 13.94 | 9.94 | 120 | 319491 | 27264 | 46339187 |
Autoimmune nephritis | 13.94 | 9.94 | 14 | 319597 | 312 | 46366139 |
Respiratory arrest | 13.93 | 9.94 | 156 | 319455 | 33660 | 46332791 |
Malabsorption | 13.87 | 9.94 | 57 | 319554 | 3726 | 46362725 |
Swollen tongue | 13.84 | 9.94 | 279 | 319332 | 28953 | 46337498 |
Anxiety | 13.84 | 9.94 | 1065 | 318546 | 180892 | 46185559 |
Diabetic foot infection | 13.84 | 9.94 | 11 | 319600 | 178 | 46366273 |
Tooth disorder | 13.79 | 9.94 | 98 | 319513 | 23205 | 46343246 |
Joint range of motion decreased | 13.75 | 9.94 | 55 | 319556 | 15069 | 46351382 |
Reactive psychosis | 13.75 | 9.94 | 4 | 319607 | 3 | 46366448 |
Cutaneous vasculitis | 13.74 | 9.94 | 59 | 319552 | 3932 | 46362519 |
Blood pressure systolic increased | 13.71 | 9.94 | 275 | 319336 | 28512 | 46337939 |
Spinal compression fracture | 13.67 | 9.94 | 44 | 319567 | 12859 | 46353592 |
Malaise | 13.65 | 9.94 | 2520 | 317091 | 328712 | 46037739 |
Hepatic enzyme increased | 13.65 | 9.94 | 441 | 319170 | 81346 | 46285105 |
Back pain | 13.62 | 9.94 | 1245 | 318366 | 208794 | 46157657 |
Wrong patient received product | 13.61 | 9.94 | 34 | 319577 | 1703 | 46364748 |
Muscle necrosis | 13.57 | 9.94 | 18 | 319593 | 546 | 46365905 |
Rash erythematous | 13.55 | 9.94 | 160 | 319451 | 34190 | 46332261 |
Drug reaction with eosinophilia and systemic symptoms | 13.52 | 9.94 | 133 | 319478 | 29415 | 46337036 |
PCO2 decreased | 13.47 | 9.94 | 28 | 319583 | 1240 | 46365211 |
Pregnancy with contraceptive device | 13.45 | 9.94 | 7 | 319604 | 4496 | 46361955 |
Blood growth hormone abnormal | 13.40 | 9.94 | 6 | 319605 | 30 | 46366421 |
Glucose urine | 13.38 | 9.94 | 5 | 319606 | 14 | 46366437 |
Hallucination | 13.35 | 9.94 | 251 | 319360 | 49700 | 46316751 |
Depression | 13.35 | 9.94 | 993 | 318618 | 169111 | 46197340 |
Asthma | 13.35 | 9.94 | 502 | 319109 | 91040 | 46275411 |
Hyponatraemia | 13.35 | 9.94 | 834 | 318777 | 100498 | 46265953 |
Postmenopausal haemorrhage | 13.32 | 9.94 | 37 | 319574 | 1976 | 46364475 |
Tumour lysis syndrome | 13.32 | 9.94 | 18 | 319593 | 7218 | 46359233 |
Increased appetite | 13.30 | 9.94 | 102 | 319509 | 8425 | 46358026 |
Thyroid cancer recurrent | 13.24 | 9.94 | 6 | 319605 | 31 | 46366420 |
Antipsychotic drug level increased | 13.24 | 9.94 | 50 | 319561 | 3142 | 46363309 |
Metastases to bone | 13.23 | 9.94 | 68 | 319543 | 17408 | 46349043 |
Venous aneurysm | 13.22 | 9.94 | 4 | 319607 | 4 | 46366447 |
Diabetic cheiroarthropathy | 13.22 | 9.94 | 4 | 319607 | 4 | 46366447 |
Injection site warmth | 13.22 | 9.94 | 49 | 319562 | 13723 | 46352728 |
Helicobacter infection | 13.16 | 9.94 | 39 | 319572 | 11697 | 46354754 |
Alkalosis hypochloraemic | 13.16 | 9.94 | 10 | 319601 | 151 | 46366300 |
Hypereosinophilic syndrome | 13.12 | 9.94 | 12 | 319599 | 237 | 46366214 |
Abnormal loss of weight | 13.08 | 9.94 | 68 | 319543 | 4907 | 46361544 |
Central nervous system lesion | 13.06 | 9.94 | 29 | 319582 | 9586 | 46356865 |
Early satiety | 13.04 | 9.94 | 21 | 319590 | 762 | 46365689 |
Adrenal neoplasm | 13.01 | 9.94 | 13 | 319598 | 288 | 46366163 |
Bladder neoplasm | 12.99 | 9.94 | 17 | 319594 | 509 | 46365942 |
Pneumonitis | 12.97 | 9.94 | 128 | 319483 | 28292 | 46338159 |
Rash maculo-papular | 12.95 | 9.94 | 125 | 319486 | 27749 | 46338702 |
Cortisol increased | 12.88 | 9.94 | 14 | 319597 | 343 | 46366108 |
Gallbladder oedema | 12.87 | 9.94 | 11 | 319600 | 198 | 46366253 |
Vascular graft | 12.86 | 9.94 | 21 | 319590 | 771 | 46365680 |
Inappropriate schedule of product administration | 12.82 | 9.94 | 556 | 319055 | 64457 | 46301994 |
Hypogammaglobulinaemia | 12.82 | 9.94 | 11 | 319600 | 5427 | 46361024 |
Hyporesponsive to stimuli | 12.81 | 9.94 | 22 | 319589 | 842 | 46365609 |
Hypoglycaemia neonatal | 12.77 | 9.94 | 23 | 319588 | 915 | 46365536 |
Hypophagia | 12.67 | 9.94 | 276 | 319335 | 29030 | 46337421 |
Pollakiuria | 12.66 | 9.94 | 235 | 319376 | 24026 | 46342425 |
Sinus arrest | 12.65 | 9.94 | 33 | 319578 | 1698 | 46364753 |
Cardio-respiratory distress | 12.59 | 9.94 | 9 | 319602 | 123 | 46366328 |
Hypertensive angiopathy | 12.58 | 9.94 | 8 | 319603 | 89 | 46366362 |
Tumour compression | 12.52 | 9.94 | 6 | 319605 | 36 | 46366415 |
Drug eruption | 12.47 | 9.94 | 90 | 319521 | 21239 | 46345212 |
Suspected suicide | 12.45 | 9.94 | 64 | 319547 | 4597 | 46361854 |
Pancreatic injury | 12.45 | 9.94 | 5 | 319606 | 18 | 46366433 |
Insulin-requiring type 2 diabetes mellitus | 12.44 | 9.94 | 7 | 319604 | 61 | 46366390 |
Enterochromaffin cell hyperplasia | 12.44 | 9.94 | 7 | 319604 | 61 | 46366390 |
Deformity | 12.42 | 9.94 | 19 | 319592 | 7238 | 46359213 |
Neoplasm malignant | 12.40 | 9.94 | 102 | 319509 | 23397 | 46343054 |
Interstitial lung disease | 12.37 | 9.94 | 278 | 319333 | 53671 | 46312780 |
Device use error | 12.32 | 9.94 | 10 | 319601 | 5071 | 46361380 |
Abortion induced | 12.31 | 9.94 | 33 | 319578 | 10227 | 46356224 |
Neuropathy peripheral | 12.26 | 9.94 | 503 | 319108 | 90390 | 46276061 |
Pancreatic neoplasm | 12.25 | 9.94 | 20 | 319591 | 734 | 46365717 |
Decreased bronchial secretion | 12.25 | 9.94 | 7 | 319604 | 63 | 46366388 |
Brain oedema | 12.24 | 9.94 | 44 | 319567 | 12434 | 46354017 |
Treatment noncompliance | 12.22 | 9.94 | 278 | 319333 | 29453 | 46336998 |
Incorrect dose administered | 12.20 | 9.94 | 403 | 319208 | 45147 | 46321304 |
Binge eating | 12.16 | 9.94 | 14 | 319597 | 366 | 46366085 |
Fibromyalgia | 12.13 | 9.94 | 176 | 319435 | 36287 | 46330164 |
Diet failure | 12.12 | 9.94 | 6 | 319605 | 39 | 46366412 |
Lupus-like syndrome | 12.07 | 9.94 | 22 | 319589 | 7822 | 46358629 |
Cholangiectasis acquired | 12.04 | 9.94 | 5 | 319606 | 20 | 46366431 |
Sprue-like enteropathy | 12.01 | 9.94 | 15 | 319596 | 428 | 46366023 |
Central obesity | 12.01 | 9.94 | 21 | 319590 | 816 | 46365635 |
Fluid retention | 12.00 | 9.94 | 262 | 319349 | 50784 | 46315667 |
Retinal artery thrombosis | 12.00 | 9.94 | 8 | 319603 | 97 | 46366354 |
Base excess decreased | 11.98 | 9.94 | 7 | 319604 | 66 | 46366385 |
Diffuse idiopathic skeletal hyperostosis | 11.97 | 9.94 | 3 | 319608 | 0 | 46366451 |
Nipple swelling | 11.97 | 9.94 | 3 | 319608 | 0 | 46366451 |
Blood corticotrophin abnormal | 11.97 | 9.94 | 3 | 319608 | 0 | 46366451 |
Blood osmolarity abnormal | 11.97 | 9.94 | 4 | 319607 | 7 | 46366444 |
Urosepsis | 11.93 | 9.94 | 159 | 319452 | 15194 | 46351257 |
Bronchiectasis | 11.92 | 9.94 | 29 | 319582 | 9287 | 46357164 |
Motor dysfunction | 11.86 | 9.94 | 88 | 319523 | 7194 | 46359257 |
Polycystic ovaries | 11.82 | 9.94 | 28 | 319583 | 1356 | 46365095 |
Anaphylactic reaction | 11.81 | 9.94 | 275 | 319336 | 52837 | 46313614 |
Eructation | 11.80 | 9.94 | 88 | 319523 | 7207 | 46359244 |
Diabetic coma | 11.79 | 9.94 | 20 | 319591 | 758 | 46365693 |
Urine ketone body | 11.78 | 9.94 | 9 | 319602 | 137 | 46366314 |
Fluid intake reduced | 11.78 | 9.94 | 50 | 319561 | 3316 | 46363135 |
Atrioventricular block complete | 11.77 | 9.94 | 91 | 319520 | 7536 | 46358915 |
Device breakage | 11.76 | 9.94 | 31 | 319580 | 9661 | 46356790 |
Transcription medication error | 11.70 | 9.94 | 10 | 319601 | 180 | 46366271 |
Conjunctivitis | 11.68 | 9.94 | 60 | 319551 | 15364 | 46351087 |
Genital erythema | 11.67 | 9.94 | 5 | 319606 | 22 | 46366429 |
Pneumonia viral | 11.67 | 9.94 | 17 | 319594 | 6607 | 46359844 |
Aplasia pure red cell | 11.64 | 9.94 | 8 | 319603 | 4417 | 46362034 |
Cervical dysplasia | 11.59 | 9.94 | 3 | 319608 | 2966 | 46363485 |
Distributive shock | 11.58 | 9.94 | 16 | 319595 | 505 | 46365946 |
Akathisia | 11.55 | 9.94 | 22 | 319589 | 7692 | 46358759 |
Uterine perforation | 11.53 | 9.94 | 20 | 319591 | 7247 | 46359204 |
Urine output increased | 11.52 | 9.94 | 26 | 319585 | 1219 | 46365232 |
Gallbladder disorder | 11.51 | 9.94 | 176 | 319435 | 17322 | 46349129 |
Dystonia | 11.51 | 9.94 | 39 | 319572 | 11218 | 46355233 |
Psychogenic tremor | 11.50 | 9.94 | 5 | 319606 | 23 | 46366428 |
Hypergastrinaemia | 11.46 | 9.94 | 8 | 319603 | 105 | 46366346 |
Neurofibrosarcoma | 11.46 | 9.94 | 9 | 319602 | 143 | 46366308 |
Left atrial dilatation | 11.46 | 9.94 | 33 | 319578 | 1800 | 46364651 |
Abortion spontaneous | 11.46 | 9.94 | 220 | 319391 | 43426 | 46323025 |
Hyperventilation | 11.44 | 9.94 | 72 | 319539 | 5575 | 46360876 |
Neuroendocrine tumour | 11.36 | 9.94 | 17 | 319594 | 578 | 46365873 |
Encephalitis | 11.36 | 9.94 | 21 | 319590 | 7427 | 46359024 |
Cell death | 11.34 | 9.94 | 38 | 319573 | 2250 | 46364201 |
Base excess | 11.33 | 9.94 | 5 | 319606 | 24 | 46366427 |
Nodular rash | 11.30 | 9.94 | 10 | 319601 | 189 | 46366262 |
Urine output decreased | 11.29 | 9.94 | 121 | 319490 | 10976 | 46355475 |
Enterococcal infection | 11.29 | 9.94 | 19 | 319592 | 6968 | 46359483 |
Muscle injury | 11.28 | 9.94 | 10 | 319601 | 4856 | 46361595 |
Mental disability | 11.27 | 9.94 | 8 | 319603 | 108 | 46366343 |
Visceral congestion | 11.27 | 9.94 | 12 | 319599 | 287 | 46366164 |
Infusion site erythema | 11.26 | 9.94 | 22 | 319589 | 7620 | 46358831 |
Low density lipoprotein increased | 11.23 | 9.94 | 75 | 319536 | 5925 | 46360526 |
Cardiac disorder | 11.23 | 9.94 | 386 | 319225 | 43472 | 46322979 |
Food craving | 11.22 | 9.94 | 25 | 319586 | 1162 | 46365289 |
Pulmonary haemorrhage | 11.16 | 9.94 | 17 | 319594 | 6488 | 46359963 |
Device deployment issue | 11.14 | 9.94 | 5 | 319606 | 3498 | 46362953 |
Haemorrhage | 11.14 | 9.94 | 288 | 319323 | 54581 | 46311870 |
Metastases to fallopian tube | 11.09 | 9.94 | 6 | 319605 | 48 | 46366403 |
Coronary angioplasty | 11.09 | 9.94 | 8 | 319603 | 111 | 46366340 |
Duodenal ulcer haemorrhage | 11.07 | 9.94 | 39 | 319572 | 2369 | 46364082 |
Vulvovaginitis | 11.04 | 9.94 | 12 | 319599 | 294 | 46366157 |
Renal cancer | 11.04 | 9.94 | 47 | 319564 | 3121 | 46363330 |
Sensory loss | 11.01 | 9.94 | 83 | 319528 | 6819 | 46359632 |
Metabolic encephalopathy | 11.01 | 9.94 | 69 | 319542 | 5334 | 46361117 |
Empty sella syndrome | 11.01 | 9.94 | 5 | 319606 | 26 | 46366425 |
Increased tendency to bruise | 10.98 | 9.94 | 31 | 319580 | 9443 | 46357008 |
Genital rash | 10.97 | 9.94 | 15 | 319596 | 469 | 46365982 |
Serum ferritin increased | 10.93 | 9.94 | 12 | 319599 | 5271 | 46361180 |
Red cell distribution width abnormal | 10.90 | 9.94 | 9 | 319602 | 154 | 46366297 |
Right ventricular failure | 10.88 | 9.94 | 65 | 319546 | 16028 | 46350423 |
Throat irritation | 10.88 | 9.94 | 136 | 319475 | 28765 | 46337686 |
Grip strength decreased | 10.85 | 9.94 | 27 | 319584 | 8579 | 46357872 |
Bacteraemia | 10.83 | 9.94 | 55 | 319556 | 14124 | 46352327 |
Spinal fracture | 10.78 | 9.94 | 61 | 319550 | 15244 | 46351207 |
Endometrial cancer stage II | 10.75 | 9.94 | 4 | 319607 | 11 | 46366440 |
IIIrd nerve paralysis | 10.75 | 9.94 | 18 | 319593 | 675 | 46365776 |
Leiomyoma | 10.74 | 9.94 | 13 | 319598 | 359 | 46366092 |
Metastases to central nervous system | 10.72 | 9.94 | 40 | 319571 | 11181 | 46355270 |
Vulvovaginal pruritus | 10.71 | 9.94 | 39 | 319572 | 2408 | 46364043 |
Enterocolitis | 10.70 | 9.94 | 16 | 319595 | 6152 | 46360299 |
Ovarian adenoma | 10.67 | 9.94 | 11 | 319600 | 253 | 46366198 |
Epistaxis | 10.67 | 9.94 | 347 | 319264 | 63958 | 46302493 |
Joint effusion | 10.67 | 9.94 | 44 | 319567 | 11951 | 46354500 |
Respiratory depression | 10.66 | 9.94 | 42 | 319569 | 11558 | 46354893 |
Gastrointestinal carcinoma | 10.65 | 9.94 | 25 | 319586 | 1203 | 46365248 |
Pulmonary tuberculosis | 10.64 | 9.94 | 10 | 319601 | 4721 | 46361730 |
Cholestatic liver injury | 10.62 | 9.94 | 35 | 319576 | 2055 | 46364396 |
Demyelination | 10.58 | 9.94 | 14 | 319597 | 5666 | 46360785 |
Hypertensive crisis | 10.58 | 9.94 | 141 | 319470 | 13474 | 46352977 |
Helicobacter gastritis | 10.57 | 9.94 | 28 | 319583 | 1454 | 46364997 |
Bradyarrhythmia | 10.56 | 9.94 | 34 | 319577 | 1972 | 46364479 |
Rhinorrhoea | 10.54 | 9.94 | 247 | 319364 | 47418 | 46319033 |
Sedation | 10.53 | 9.94 | 103 | 319508 | 22807 | 46343644 |
Inappropriate antidiuretic hormone secretion | 10.53 | 9.94 | 145 | 319466 | 13957 | 46352494 |
Lichen planus | 10.51 | 9.94 | 32 | 319579 | 1801 | 46364650 |
Sudden cardiac death | 10.48 | 9.94 | 36 | 319575 | 2159 | 46364292 |
Neutropenic sepsis | 10.47 | 9.94 | 46 | 319565 | 12278 | 46354173 |
Acid base balance abnormal | 10.47 | 9.94 | 11 | 319600 | 259 | 46366192 |
Incision site swelling | 10.43 | 9.94 | 5 | 319606 | 30 | 46366421 |
Blood urea increased | 10.40 | 9.94 | 237 | 319374 | 25115 | 46341336 |
Endometrial hyperplasia | 10.39 | 9.94 | 19 | 319592 | 765 | 46365686 |
Sepsis | 10.35 | 9.94 | 796 | 318815 | 135218 | 46231233 |
Skin lesion | 10.32 | 9.94 | 125 | 319486 | 26588 | 46339863 |
Genital infection | 10.32 | 9.94 | 6 | 319605 | 56 | 46366395 |
Malnutrition | 10.31 | 9.94 | 55 | 319556 | 13948 | 46352503 |
Blood bicarbonate abnormal | 10.30 | 9.94 | 5 | 319606 | 31 | 46366420 |
Pancreatic pseudocyst | 10.29 | 9.94 | 16 | 319595 | 563 | 46365888 |
Mood swings | 10.28 | 9.94 | 67 | 319544 | 16185 | 46350266 |
Benign pancreatic neoplasm | 10.27 | 9.94 | 4 | 319607 | 13 | 46366438 |
Influenza like illness | 10.19 | 9.94 | 308 | 319303 | 57262 | 46309189 |
Alanine aminotransferase increased | 10.19 | 9.94 | 498 | 319113 | 87953 | 46278498 |
Skin turgor decreased | 10.18 | 9.94 | 15 | 319596 | 503 | 46365948 |
Hypoglycaemic seizure | 10.18 | 9.94 | 15 | 319596 | 503 | 46365948 |
Renal injury | 10.16 | 9.94 | 105 | 319506 | 9436 | 46357015 |
Emphysematous pyelonephritis | 10.09 | 9.94 | 9 | 319602 | 172 | 46366279 |
Foetal hypokinesia | 10.08 | 9.94 | 14 | 319597 | 444 | 46366007 |
Skin necrosis | 10.08 | 9.94 | 28 | 319583 | 8576 | 46357875 |
Drug half-life increased | 10.04 | 9.94 | 4 | 319607 | 14 | 46366437 |
Retinal vascular disorder | 10.00 | 9.94 | 9 | 319602 | 174 | 46366277 |
Hypertensive emergency | 9.99 | 9.94 | 29 | 319582 | 1589 | 46364862 |
Miosis | 9.95 | 9.94 | 19 | 319592 | 6638 | 46359813 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lactic acidosis | 8786.04 | 11.09 | 4738 | 275873 | 26475 | 29645392 |
Hypoglycaemia | 1846.37 | 11.09 | 2330 | 278281 | 48651 | 29623216 |
Diabetic ketoacidosis | 1698.41 | 11.09 | 1317 | 279294 | 14669 | 29657198 |
Acute kidney injury | 1605.85 | 11.09 | 5908 | 274703 | 267934 | 29403933 |
Blood glucose increased | 1241.23 | 11.09 | 2135 | 278476 | 59395 | 29612472 |
Metabolic acidosis | 1225.49 | 11.09 | 1629 | 278982 | 35832 | 29636035 |
Glycosylated haemoglobin increased | 774.66 | 11.09 | 671 | 279940 | 8820 | 29663047 |
Diabetes mellitus inadequate control | 740.11 | 11.09 | 746 | 279865 | 12016 | 29659851 |
Euglycaemic diabetic ketoacidosis | 618.43 | 11.09 | 317 | 280294 | 1554 | 29670313 |
Myocardial infarction | 613.65 | 11.09 | 2565 | 278046 | 123060 | 29548807 |
Hyperkalaemia | 571.94 | 11.09 | 1632 | 278979 | 64378 | 29607489 |
Ketoacidosis | 529.76 | 11.09 | 367 | 280244 | 3379 | 29668488 |
Pancreatitis | 514.43 | 11.09 | 1088 | 279523 | 35402 | 29636465 |
Hyperglycaemia | 461.23 | 11.09 | 1019 | 279592 | 34181 | 29637686 |
Coronary artery disease | 443.05 | 11.09 | 1242 | 279369 | 48470 | 29623397 |
Pancreatitis acute | 353.80 | 11.09 | 759 | 279852 | 24936 | 29646931 |
Drug abuse | 320.95 | 11.09 | 185 | 280426 | 81887 | 29589980 |
Death | 317.41 | 11.09 | 2006 | 278605 | 355277 | 29316590 |
Pemphigoid | 299.15 | 11.09 | 361 | 280250 | 7167 | 29664700 |
Hyperlactacidaemia | 281.57 | 11.09 | 217 | 280394 | 2389 | 29669478 |
Cardiac failure congestive | 264.32 | 11.09 | 1519 | 279092 | 82888 | 29588979 |
Febrile neutropenia | 252.73 | 11.09 | 380 | 280231 | 106313 | 29565554 |
Pancreatic carcinoma | 250.09 | 11.09 | 337 | 280274 | 7500 | 29664367 |
Pyrexia | 248.16 | 11.09 | 1679 | 278932 | 292810 | 29379057 |
Off label use | 240.71 | 11.09 | 1362 | 279249 | 247928 | 29423939 |
Neutropenia | 226.34 | 11.09 | 547 | 280064 | 127993 | 29543874 |
Diabetic metabolic decompensation | 224.21 | 11.09 | 146 | 280465 | 1200 | 29670667 |
Hypoglycaemic coma | 221.56 | 11.09 | 180 | 280431 | 2151 | 29669716 |
Pneumonia | 208.88 | 11.09 | 2065 | 278546 | 332241 | 29339626 |
Blood glucose abnormal | 208.64 | 11.09 | 252 | 280359 | 5007 | 29666860 |
Blood lactic acid increased | 203.50 | 11.09 | 262 | 280349 | 5568 | 29666299 |
Shock | 203.36 | 11.09 | 571 | 280040 | 22288 | 29649579 |
Bladder cancer | 196.56 | 11.09 | 326 | 280285 | 8776 | 29663091 |
Blood glucose decreased | 194.09 | 11.09 | 398 | 280213 | 12655 | 29659212 |
Blood glucose fluctuation | 194.09 | 11.09 | 204 | 280407 | 3457 | 29668410 |
Diabetes mellitus | 192.31 | 11.09 | 840 | 279771 | 41025 | 29630842 |
Type 2 diabetes mellitus | 163.45 | 11.09 | 381 | 280230 | 13241 | 29658626 |
Platelet count decreased | 162.29 | 11.09 | 484 | 280127 | 105645 | 29566222 |
Drug ineffective | 159.36 | 11.09 | 2240 | 278371 | 338147 | 29333720 |
Product use in unapproved indication | 147.41 | 11.09 | 292 | 280319 | 73401 | 29598466 |
Cerebrovascular accident | 146.78 | 11.09 | 1307 | 279304 | 82170 | 29589697 |
Cytomegalovirus infection | 146.74 | 11.09 | 23 | 280588 | 23651 | 29648216 |
Thrombocytopenia | 141.72 | 11.09 | 731 | 279880 | 136313 | 29535554 |
Pancytopenia | 137.99 | 11.09 | 377 | 280234 | 84675 | 29587192 |
Ketonuria | 137.58 | 11.09 | 80 | 280531 | 524 | 29671343 |
Intentional overdose | 135.94 | 11.09 | 756 | 279855 | 40725 | 29631142 |
Diabetic neuropathy | 133.63 | 11.09 | 175 | 280436 | 3784 | 29668083 |
Weight decreased | 128.42 | 11.09 | 2056 | 278555 | 148865 | 29523002 |
White blood cell count decreased | 123.90 | 11.09 | 389 | 280222 | 83558 | 29588309 |
Vitamin B12 deficiency | 123.78 | 11.09 | 137 | 280474 | 2468 | 29669399 |
Anuria | 123.18 | 11.09 | 288 | 280323 | 10028 | 29661839 |
Coronary artery bypass | 122.51 | 11.09 | 193 | 280418 | 4969 | 29666898 |
Leukopenia | 115.35 | 11.09 | 219 | 280392 | 55940 | 29615927 |
Seizure | 114.17 | 11.09 | 504 | 280107 | 97971 | 29573896 |
Pancreatic carcinoma metastatic | 110.32 | 11.09 | 144 | 280467 | 3103 | 29668764 |
Rheumatoid arthritis | 109.26 | 11.09 | 135 | 280476 | 41062 | 29630805 |
Bone marrow failure | 106.90 | 11.09 | 74 | 280537 | 29711 | 29642156 |
Plasma cell myeloma | 105.89 | 11.09 | 213 | 280398 | 53249 | 29618618 |
Lipase increased | 104.45 | 11.09 | 243 | 280368 | 8433 | 29663434 |
Toe amputation | 103.29 | 11.09 | 116 | 280495 | 2125 | 29669742 |
Drug resistance | 101.68 | 11.09 | 31 | 280580 | 20102 | 29651765 |
Myocardial ischaemia | 101.52 | 11.09 | 375 | 280236 | 16942 | 29654925 |
Acidosis | 101.27 | 11.09 | 267 | 280344 | 10034 | 29661833 |
Acute myocardial infarction | 100.89 | 11.09 | 844 | 279767 | 52095 | 29619772 |
Product residue present | 97.65 | 11.09 | 123 | 280488 | 2555 | 29669312 |
Treatment failure | 96.93 | 11.09 | 109 | 280502 | 34570 | 29637297 |
Neutrophil count decreased | 96.77 | 11.09 | 155 | 280456 | 42299 | 29629568 |
Disease progression | 96.73 | 11.09 | 402 | 280209 | 79472 | 29592395 |
Completed suicide | 95.95 | 11.09 | 1385 | 279226 | 98107 | 29573760 |
Anion gap increased | 95.10 | 11.09 | 97 | 280514 | 1584 | 29670283 |
Renal failure | 92.28 | 11.09 | 1709 | 278902 | 127257 | 29544610 |
Infusion related reaction | 87.01 | 11.09 | 154 | 280457 | 40410 | 29631457 |
Continuous haemodiafiltration | 84.12 | 11.09 | 75 | 280536 | 1026 | 29670841 |
Vomiting | 82.60 | 11.09 | 2667 | 277944 | 217151 | 29454716 |
Heart injury | 80.06 | 11.09 | 83 | 280528 | 1383 | 29670484 |
Injection site nodule | 78.64 | 11.09 | 82 | 280529 | 1376 | 29670491 |
Pneumocystis jirovecii pneumonia | 78.47 | 11.09 | 31 | 280580 | 17089 | 29654778 |
Graft versus host disease | 78.43 | 11.09 | 4 | 280607 | 10146 | 29661721 |
Polyuria | 77.63 | 11.09 | 195 | 280416 | 7111 | 29664756 |
Urine ketone body present | 77.41 | 11.09 | 68 | 280543 | 911 | 29670956 |
Malignant neoplasm progression | 75.51 | 11.09 | 384 | 280227 | 71903 | 29599964 |
Adenocarcinoma pancreas | 75.22 | 11.09 | 78 | 280533 | 1300 | 29670567 |
Ketosis | 75.16 | 11.09 | 46 | 280565 | 335 | 29671532 |
Drug dependence | 73.67 | 11.09 | 55 | 280556 | 21240 | 29650627 |
Toxic epidermal necrolysis | 73.60 | 11.09 | 38 | 280573 | 17902 | 29653965 |
Hepatic function abnormal | 73.29 | 11.09 | 179 | 280432 | 41766 | 29630101 |
Immune-mediated myositis | 72.43 | 11.09 | 74 | 280537 | 1211 | 29670656 |
Coronary arterial stent insertion | 72.17 | 11.09 | 136 | 280475 | 4058 | 29667809 |
Pancreatitis chronic | 71.60 | 11.09 | 86 | 280525 | 1698 | 29670169 |
Diabetic retinopathy | 71.29 | 11.09 | 85 | 280526 | 1665 | 29670202 |
Infective pulmonary exacerbation of cystic fibrosis | 67.46 | 11.09 | 3 | 280608 | 8569 | 29663298 |
Alanine aminotransferase increased | 67.02 | 11.09 | 414 | 280197 | 73862 | 29598005 |
Stomatitis | 65.99 | 11.09 | 158 | 280453 | 37121 | 29634746 |
Haemodialysis | 65.08 | 11.09 | 240 | 280371 | 10833 | 29661034 |
Bronchopulmonary aspergillosis | 63.71 | 11.09 | 18 | 280593 | 12266 | 29659601 |
Aspartate aminotransferase increased | 63.38 | 11.09 | 342 | 280269 | 63080 | 29608787 |
Diarrhoea | 61.35 | 11.09 | 3766 | 276845 | 330337 | 29341530 |
Angina unstable | 61.12 | 11.09 | 253 | 280358 | 12057 | 29659810 |
Diabetic foot infection | 61.08 | 11.09 | 52 | 280559 | 666 | 29671201 |
Aspergillus infection | 60.91 | 11.09 | 11 | 280600 | 10203 | 29661664 |
Hypomagnesaemia | 60.81 | 11.09 | 312 | 280299 | 16286 | 29655581 |
Balanoposthitis | 60.71 | 11.09 | 62 | 280549 | 1014 | 29670853 |
MELAS syndrome | 60.13 | 11.09 | 19 | 280592 | 13 | 29671854 |
Peritonitis | 59.93 | 11.09 | 67 | 280544 | 21308 | 29650559 |
Acetonaemia | 59.28 | 11.09 | 25 | 280586 | 70 | 29671797 |
Transplant rejection | 59.24 | 11.09 | 8 | 280603 | 9198 | 29662669 |
Rash | 58.02 | 11.09 | 1362 | 279249 | 190527 | 29481340 |
Blood lactic acid | 57.92 | 11.09 | 39 | 280572 | 341 | 29671526 |
Posterior reversible encephalopathy syndrome | 57.39 | 11.09 | 7 | 280604 | 8700 | 29663167 |
Acute coronary syndrome | 56.05 | 11.09 | 264 | 280347 | 13309 | 29658558 |
Infection | 55.48 | 11.09 | 466 | 280145 | 77608 | 29594259 |
Sepsis | 54.90 | 11.09 | 1003 | 279608 | 145392 | 29526475 |
Peritonitis bacterial | 54.84 | 11.09 | 19 | 280592 | 11359 | 29660508 |
Condition aggravated | 54.74 | 11.09 | 935 | 279676 | 136931 | 29534936 |
Ischaemic cardiomyopathy | 54.71 | 11.09 | 156 | 280455 | 6141 | 29665726 |
Neuropathy peripheral | 54.06 | 11.09 | 412 | 280199 | 70063 | 29601804 |
Pancreatic neoplasm | 53.64 | 11.09 | 55 | 280556 | 904 | 29670963 |
Septic shock | 53.57 | 11.09 | 362 | 280249 | 63245 | 29608622 |
Drug intolerance | 53.53 | 11.09 | 230 | 280381 | 45061 | 29626806 |
Hallucination | 53.29 | 11.09 | 257 | 280354 | 48802 | 29623065 |
Intentional product use issue | 52.91 | 11.09 | 170 | 280441 | 36270 | 29635597 |
Kidney transplant rejection | 52.14 | 11.09 | 5 | 280606 | 7504 | 29664363 |
Microalbuminuria | 52.13 | 11.09 | 45 | 280566 | 588 | 29671279 |
Immune reconstitution inflammatory syndrome | 51.75 | 11.09 | 11 | 280600 | 9090 | 29662777 |
Suicide attempt | 50.90 | 11.09 | 547 | 280064 | 36150 | 29635717 |
Drug level increased | 50.75 | 11.09 | 320 | 280291 | 18034 | 29653833 |
Blood pH decreased | 50.62 | 11.09 | 83 | 280528 | 2212 | 29669655 |
Hospitalisation | 50.60 | 11.09 | 228 | 280383 | 44091 | 29627776 |
Aggression | 50.30 | 11.09 | 177 | 280434 | 36730 | 29635137 |
Pathogen resistance | 50.27 | 11.09 | 9 | 280602 | 8401 | 29663466 |
Diabetic nephropathy | 50.17 | 11.09 | 74 | 280537 | 1795 | 29670072 |
Haemoglobin decreased | 49.53 | 11.09 | 761 | 279850 | 113337 | 29558530 |
Disseminated intravascular coagulation | 49.53 | 11.09 | 82 | 280529 | 22089 | 29649778 |
Hypoxia | 49.51 | 11.09 | 255 | 280356 | 47599 | 29624268 |
Interstitial lung disease | 49.50 | 11.09 | 345 | 280266 | 59852 | 29612015 |
Latent autoimmune diabetes in adults | 49.23 | 11.09 | 18 | 280593 | 29 | 29671838 |
Cardiovascular disorder | 48.16 | 11.09 | 217 | 280394 | 10735 | 29661132 |
Dehydration | 48.13 | 11.09 | 1506 | 279105 | 122033 | 29549834 |
Genital infection fungal | 47.94 | 11.09 | 27 | 280584 | 165 | 29671702 |
Hypothermia | 47.01 | 11.09 | 196 | 280415 | 9371 | 29662496 |
Mucosal inflammation | 46.59 | 11.09 | 139 | 280472 | 30355 | 29641512 |
Glomerular filtration rate decreased | 46.19 | 11.09 | 220 | 280391 | 11142 | 29660725 |
Obesity | 44.99 | 11.09 | 179 | 280432 | 8376 | 29663491 |
Foetal exposure during pregnancy | 44.95 | 11.09 | 185 | 280426 | 36686 | 29635181 |
Lymphocyte count decreased | 44.91 | 11.09 | 68 | 280543 | 18987 | 29652880 |
Blood ketone body increased | 44.51 | 11.09 | 33 | 280578 | 341 | 29671526 |
Urine albumin/creatinine ratio abnormal | 44.16 | 11.09 | 12 | 280599 | 0 | 29671867 |
Product odour abnormal | 44.12 | 11.09 | 40 | 280571 | 560 | 29671307 |
Anxiety | 44.07 | 11.09 | 585 | 280026 | 89286 | 29582581 |
Osteonecrosis | 43.69 | 11.09 | 52 | 280559 | 16083 | 29655784 |
Drug reaction with eosinophilia and systemic symptoms | 43.42 | 11.09 | 130 | 280481 | 28358 | 29643509 |
Haemophagocytic lymphohistiocytosis | 42.82 | 11.09 | 19 | 280592 | 9772 | 29662095 |
Clostridium difficile infection | 42.59 | 11.09 | 51 | 280560 | 15732 | 29656135 |
Cytokine release syndrome | 42.32 | 11.09 | 20 | 280591 | 9913 | 29661954 |
Urine ketone body | 41.25 | 11.09 | 17 | 280594 | 44 | 29671823 |
Deep vein thrombosis | 41.24 | 11.09 | 365 | 280246 | 60136 | 29611731 |
Glycosylated haemoglobin decreased | 40.99 | 11.09 | 31 | 280580 | 331 | 29671536 |
Pseudomonas infection | 40.40 | 11.09 | 24 | 280587 | 10458 | 29661409 |
Angina pectoris | 40.01 | 11.09 | 438 | 280173 | 29080 | 29642787 |
Hepatic steatosis | 39.71 | 11.09 | 256 | 280355 | 14537 | 29657330 |
Cardiogenic shock | 39.42 | 11.09 | 282 | 280329 | 16579 | 29655288 |
Cytomegalovirus viraemia | 39.29 | 11.09 | 4 | 280607 | 5725 | 29666142 |
Polydipsia | 38.98 | 11.09 | 97 | 280514 | 3516 | 29668351 |
Suspected suicide | 38.56 | 11.09 | 89 | 280522 | 3072 | 29668795 |
Insomnia | 38.32 | 11.09 | 629 | 279982 | 92707 | 29579160 |
Synovitis | 38.27 | 11.09 | 22 | 280589 | 9761 | 29662106 |
Anaemia | 37.96 | 11.09 | 1578 | 279033 | 206414 | 29465453 |
Arteriosclerosis | 37.18 | 11.09 | 200 | 280411 | 10633 | 29661234 |
Progressive multifocal leukoencephalopathy | 37.11 | 11.09 | 19 | 280592 | 8994 | 29662873 |
Exposure via ingestion | 36.92 | 11.09 | 78 | 280533 | 2533 | 29669334 |
Osmolar gap increased | 36.80 | 11.09 | 10 | 280601 | 0 | 29671867 |
Joint swelling | 36.68 | 11.09 | 273 | 280338 | 46673 | 29625194 |
Epstein-Barr virus infection | 36.34 | 11.09 | 9 | 280602 | 6697 | 29665170 |
Obstructive pancreatitis | 36.22 | 11.09 | 30 | 280581 | 369 | 29671498 |
Starvation ketoacidosis | 35.95 | 11.09 | 12 | 280599 | 12 | 29671855 |
Tongue oedema | 35.83 | 11.09 | 80 | 280531 | 2700 | 29669167 |
Therapy non-responder | 35.77 | 11.09 | 148 | 280463 | 29305 | 29642562 |
Glycosylated haemoglobin abnormal | 35.63 | 11.09 | 18 | 280593 | 85 | 29671782 |
Arthralgia | 35.57 | 11.09 | 984 | 279627 | 134807 | 29537060 |
Musculoskeletal stiffness | 35.55 | 11.09 | 194 | 280417 | 35687 | 29636180 |
Chills | 35.41 | 11.09 | 471 | 280140 | 71867 | 29600000 |
Diabetic foot | 35.38 | 11.09 | 79 | 280532 | 2666 | 29669201 |
Osteonecrosis of jaw | 35.30 | 11.09 | 76 | 280535 | 18542 | 29653325 |
Therapeutic product effect decreased | 34.75 | 11.09 | 147 | 280464 | 28929 | 29642938 |
Drug hypersensitivity | 34.69 | 11.09 | 443 | 280168 | 68076 | 29603791 |
Blood bicarbonate decreased | 34.31 | 11.09 | 72 | 280539 | 2327 | 29669540 |
Osmolar gap | 34.13 | 11.09 | 13 | 280598 | 25 | 29671842 |
Neurotoxicity | 34.10 | 11.09 | 44 | 280567 | 13138 | 29658729 |
Myelosuppression | 33.98 | 11.09 | 13 | 280598 | 7309 | 29664558 |
Stevens-Johnson syndrome | 33.84 | 11.09 | 71 | 280540 | 17485 | 29654382 |
Vitamin B12 decreased | 33.53 | 11.09 | 45 | 280566 | 997 | 29670870 |
Exposure during pregnancy | 33.23 | 11.09 | 23 | 280588 | 9238 | 29662629 |
Respiratory arrest | 33.10 | 11.09 | 151 | 280460 | 29107 | 29642760 |
Overdose | 32.51 | 11.09 | 1027 | 279584 | 83310 | 29588557 |
Glycosuria | 32.48 | 11.09 | 50 | 280561 | 1261 | 29670606 |
Diabetic ketoacidotic hyperglycaemic coma | 32.31 | 11.09 | 20 | 280591 | 149 | 29671718 |
Thirst | 32.31 | 11.09 | 140 | 280471 | 6809 | 29665058 |
Pancreatic neuroendocrine tumour | 32.30 | 11.09 | 23 | 280588 | 222 | 29671645 |
Pancreaticoduodenectomy | 32.20 | 11.09 | 15 | 280596 | 57 | 29671810 |
Pollakiuria | 31.89 | 11.09 | 269 | 280342 | 16637 | 29655230 |
Pulmonary haemorrhage | 31.54 | 11.09 | 25 | 280586 | 9367 | 29662500 |
Naevus flammeus | 31.42 | 11.09 | 19 | 280592 | 135 | 29671732 |
Abdominal pain | 31.41 | 11.09 | 1563 | 279048 | 134091 | 29537776 |
Glucose urine present | 31.28 | 11.09 | 41 | 280570 | 887 | 29670980 |
Epilepsy | 30.76 | 11.09 | 92 | 280519 | 20077 | 29651790 |
Neoplasm progression | 30.63 | 11.09 | 78 | 280533 | 17945 | 29653922 |
Nephrogenic systemic fibrosis | 30.11 | 11.09 | 3 | 280608 | 4368 | 29667499 |
Pneumothorax | 29.96 | 11.09 | 67 | 280544 | 16126 | 29655741 |
Bladder transitional cell carcinoma | 29.85 | 11.09 | 69 | 280542 | 2384 | 29669483 |
Coma | 29.54 | 11.09 | 538 | 280073 | 39911 | 29631956 |
Myelodysplastic syndrome | 29.11 | 11.09 | 85 | 280526 | 18693 | 29653174 |
Anion gap | 29.03 | 11.09 | 33 | 280578 | 613 | 29671254 |
Dystonia | 28.93 | 11.09 | 29 | 280582 | 9698 | 29662169 |
Haemodynamic instability | 28.89 | 11.09 | 150 | 280461 | 7865 | 29664002 |
Sinusitis | 28.45 | 11.09 | 189 | 280422 | 33156 | 29638711 |
C-reactive protein increased | 28.43 | 11.09 | 265 | 280346 | 43208 | 29628659 |
Haemoptysis | 28.12 | 11.09 | 173 | 280438 | 30905 | 29640962 |
Cholelithiasis | 27.81 | 11.09 | 301 | 280310 | 19924 | 29651943 |
Depression | 27.79 | 11.09 | 640 | 279971 | 89797 | 29582070 |
Hypoalbuminaemia | 27.70 | 11.09 | 38 | 280573 | 11054 | 29660813 |
Colitis | 27.66 | 11.09 | 172 | 280439 | 30648 | 29641219 |
Bile duct stent insertion | 27.54 | 11.09 | 15 | 280596 | 85 | 29671782 |
Staphylococcal infection | 27.48 | 11.09 | 168 | 280443 | 30056 | 29641811 |
Pain | 27.34 | 11.09 | 1330 | 279281 | 171311 | 29500556 |
Distributive shock | 27.34 | 11.09 | 32 | 280579 | 614 | 29671253 |
Substance abuse | 27.30 | 11.09 | 16 | 280595 | 7024 | 29664843 |
Antipsychotic drug level decreased | 27.19 | 11.09 | 37 | 280574 | 831 | 29671036 |
Urine output increased | 27.13 | 11.09 | 41 | 280570 | 1017 | 29670850 |
Headache | 27.04 | 11.09 | 1414 | 279197 | 180892 | 29490975 |
Haematotoxicity | 26.94 | 11.09 | 12 | 280599 | 6158 | 29665709 |
Drug interaction | 26.82 | 11.09 | 2194 | 278417 | 197374 | 29474493 |
Haemorrhage | 26.76 | 11.09 | 289 | 280322 | 45790 | 29626077 |
Therapeutic response decreased | 26.75 | 11.09 | 127 | 280484 | 24222 | 29647645 |
Diabetic ketosis | 26.72 | 11.09 | 12 | 280599 | 41 | 29671826 |
Herpes zoster | 26.41 | 11.09 | 168 | 280443 | 29775 | 29642092 |
Diabetic eye disease | 26.31 | 11.09 | 13 | 280598 | 58 | 29671809 |
Pneumonia aspiration | 26.14 | 11.09 | 227 | 280384 | 37553 | 29634314 |
Acute myeloid leukaemia | 26.13 | 11.09 | 84 | 280527 | 17922 | 29653945 |
Delirium | 26 | 11.09 | 249 | 280362 | 40382 | 29631485 |
Macular oedema | 25.93 | 11.09 | 70 | 280541 | 2668 | 29669199 |
Suicidal ideation | 25.88 | 11.09 | 215 | 280396 | 35899 | 29635968 |
C-reactive protein abnormal | 25.84 | 11.09 | 10 | 280601 | 5583 | 29666284 |
Alveolar capillary dysplasia | 25.76 | 11.09 | 7 | 280604 | 0 | 29671867 |
Migraine | 25.72 | 11.09 | 51 | 280560 | 12823 | 29659044 |
Unevaluable event | 25.71 | 11.09 | 183 | 280428 | 31602 | 29640265 |
Diabetic macroangiopathy | 25.60 | 11.09 | 8 | 280603 | 5 | 29671862 |
Intestinal obstruction | 25.60 | 11.09 | 93 | 280518 | 19119 | 29652748 |
Psychotic disorder | 25.57 | 11.09 | 109 | 280502 | 21406 | 29650461 |
Blood triglycerides increased | 25.37 | 11.09 | 221 | 280390 | 13796 | 29658071 |
Blood ketone body | 25.31 | 11.09 | 13 | 280598 | 64 | 29671803 |
Toxicity to various agents | 25.12 | 11.09 | 1956 | 278655 | 175227 | 29496640 |
Enterococcal infection | 25.06 | 11.09 | 24 | 280587 | 8200 | 29663667 |
Arteriosclerosis coronary artery | 25.02 | 11.09 | 185 | 280426 | 10991 | 29660876 |
Product use issue | 24.99 | 11.09 | 293 | 280318 | 45723 | 29626144 |
Pancreatic pseudocyst | 24.88 | 11.09 | 34 | 280577 | 767 | 29671100 |
Drug withdrawal syndrome | 24.39 | 11.09 | 99 | 280512 | 19710 | 29652157 |
Basilar artery thrombosis | 24.31 | 11.09 | 15 | 280596 | 111 | 29671756 |
Balanitis candida | 24.20 | 11.09 | 15 | 280596 | 112 | 29671755 |
Vitreous haemorrhage | 24.20 | 11.09 | 58 | 280553 | 2052 | 29669815 |
Immunosuppressant drug level increased | 24.18 | 11.09 | 7 | 280604 | 4695 | 29667172 |
Restlessness | 24.17 | 11.09 | 119 | 280492 | 22480 | 29649387 |
Respiratory failure | 24.15 | 11.09 | 738 | 279873 | 99904 | 29571963 |
Epistaxis | 24.12 | 11.09 | 350 | 280261 | 52631 | 29619236 |
Thrombotic microangiopathy | 24.12 | 11.09 | 27 | 280584 | 8583 | 29663284 |
Blood lactate dehydrogenase increased | 24.10 | 11.09 | 105 | 280506 | 20496 | 29651371 |
Blood bilirubin increased | 24.09 | 11.09 | 223 | 280388 | 36413 | 29635454 |
5-hydroxyindolacetic acid in urine increased | 23.81 | 11.09 | 18 | 280593 | 192 | 29671675 |
Actinic elastosis | 23.78 | 11.09 | 11 | 280600 | 41 | 29671826 |
Intestinal perforation | 23.55 | 11.09 | 27 | 280584 | 8492 | 29663375 |
Blood mercury abnormal | 23.55 | 11.09 | 17 | 280594 | 168 | 29671699 |
Anaemia vitamin B12 deficiency | 23.45 | 11.09 | 21 | 280590 | 289 | 29671578 |
Premature baby | 23.44 | 11.09 | 79 | 280532 | 16612 | 29655255 |
Acquired phimosis | 23.38 | 11.09 | 12 | 280599 | 59 | 29671808 |
Renal tubular necrosis | 23.35 | 11.09 | 232 | 280379 | 15019 | 29656848 |
Nasopharyngitis | 23.35 | 11.09 | 399 | 280212 | 58450 | 29613417 |
Osteoporosis | 23.29 | 11.09 | 40 | 280571 | 10623 | 29661244 |
Hyperoxaluria | 22.96 | 11.09 | 15 | 280596 | 124 | 29671743 |
Essential hypertension | 22.95 | 11.09 | 63 | 280548 | 2425 | 29669442 |
Neuropathic arthropathy | 22.68 | 11.09 | 16 | 280595 | 152 | 29671715 |
Phimosis | 22.56 | 11.09 | 29 | 280582 | 615 | 29671252 |
Productive cough | 22.53 | 11.09 | 176 | 280435 | 29777 | 29642090 |
Cornea verticillata | 22.52 | 11.09 | 10 | 280601 | 33 | 29671834 |
Tumour lysis syndrome | 22.49 | 11.09 | 55 | 280556 | 12830 | 29659037 |
Transient ischaemic attack | 22.36 | 11.09 | 346 | 280265 | 24854 | 29647013 |
Lymphopenia | 22.34 | 11.09 | 57 | 280554 | 13106 | 29658761 |
Ileus | 22.27 | 11.09 | 73 | 280538 | 15482 | 29656385 |
Device related infection | 22.25 | 11.09 | 83 | 280528 | 16932 | 29654935 |
Pancreatitis necrotising | 22.22 | 11.09 | 61 | 280550 | 2348 | 29669519 |
Cardiomyopathy | 22.06 | 11.09 | 228 | 280383 | 14915 | 29656952 |
Pancreatic carcinoma stage III | 22.03 | 11.09 | 7 | 280604 | 5 | 29671862 |
Hypoglycaemic encephalopathy | 22.02 | 11.09 | 18 | 280593 | 217 | 29671650 |
Abnormal behaviour | 21.97 | 11.09 | 145 | 280466 | 25478 | 29646389 |
Drug level above therapeutic | 21.93 | 11.09 | 69 | 280542 | 2870 | 29668997 |
Pneumonia bacterial | 21.73 | 11.09 | 34 | 280577 | 9369 | 29662498 |
Food aversion | 21.66 | 11.09 | 20 | 280591 | 287 | 29671580 |
Serotonin syndrome | 21.66 | 11.09 | 90 | 280521 | 17801 | 29654066 |
Cytomegalovirus test positive | 21.57 | 11.09 | 4 | 280607 | 3641 | 29668226 |
Low density lipoprotein abnormal | 21.48 | 11.09 | 19 | 280592 | 257 | 29671610 |
Therapeutic product effect incomplete | 21.37 | 11.09 | 208 | 280403 | 33626 | 29638241 |
Tremor | 21.31 | 11.09 | 540 | 280071 | 74823 | 29597044 |
Burkholderia pseudomallei infection | 21.27 | 11.09 | 10 | 280601 | 39 | 29671828 |
Albumin urine present | 21.15 | 11.09 | 22 | 280589 | 368 | 29671499 |
Hypotension | 21.03 | 11.09 | 2166 | 278445 | 198399 | 29473468 |
Nausea | 21.00 | 11.09 | 3129 | 277482 | 293828 | 29378039 |
Cytopenia | 20.90 | 11.09 | 28 | 280583 | 8228 | 29663639 |
Renal oncocytoma | 20.89 | 11.09 | 9 | 280602 | 27 | 29671840 |
Pancreatic carcinoma stage IV | 20.88 | 11.09 | 13 | 280598 | 98 | 29671769 |
pH body fluid abnormal | 20.80 | 11.09 | 8 | 280603 | 16 | 29671851 |
Drug use disorder | 20.48 | 11.09 | 3 | 280608 | 3245 | 29668622 |
Clostridium difficile colitis | 20.37 | 11.09 | 57 | 280554 | 12711 | 29659156 |
Staphylococcal bacteraemia | 20.33 | 11.09 | 20 | 280591 | 6748 | 29665119 |
Metastases to liver | 20.30 | 11.09 | 186 | 280425 | 11779 | 29660088 |
Pulmonary alveolar haemorrhage | 20.29 | 11.09 | 19 | 280592 | 6562 | 29665305 |
Syncope | 20.20 | 11.09 | 981 | 279630 | 83922 | 29587945 |
Amylase increased | 20.15 | 11.09 | 108 | 280503 | 5733 | 29666134 |
End stage renal disease | 20.09 | 11.09 | 24 | 280587 | 7411 | 29664456 |
Gangrene | 19.97 | 11.09 | 91 | 280520 | 4523 | 29667344 |
Upper respiratory tract infection | 19.95 | 11.09 | 163 | 280448 | 27313 | 29644554 |
Palmar-plantar erythrodysaesthesia syndrome | 19.80 | 11.09 | 72 | 280539 | 14798 | 29657069 |
Haematocrit decreased | 19.70 | 11.09 | 188 | 280423 | 30511 | 29641356 |
Pancreatic stent placement | 19.60 | 11.09 | 8 | 280603 | 20 | 29671847 |
Genital candidiasis | 19.56 | 11.09 | 11 | 280600 | 67 | 29671800 |
Electrocardiogram QT prolonged | 19.52 | 11.09 | 228 | 280383 | 35607 | 29636260 |
Pulmonary embolism | 19.47 | 11.09 | 570 | 280041 | 77565 | 29594302 |
Diffuse large B-cell lymphoma | 19.44 | 11.09 | 27 | 280584 | 7814 | 29664053 |
Pleural effusion | 19.29 | 11.09 | 537 | 280074 | 73529 | 29598338 |
Autoimmune pancreatitis | 19.29 | 11.09 | 18 | 280593 | 262 | 29671605 |
Mucosal dryness | 19.24 | 11.09 | 35 | 280576 | 1016 | 29670851 |
Foot amputation | 19.23 | 11.09 | 23 | 280588 | 452 | 29671415 |
Disease recurrence | 19.23 | 11.09 | 68 | 280543 | 14093 | 29657774 |
Liver disorder | 19.08 | 11.09 | 182 | 280429 | 29540 | 29642327 |
Oxygen saturation decreased | 19.07 | 11.09 | 289 | 280322 | 43151 | 29628716 |
Anaphylactic reaction | 18.97 | 11.09 | 169 | 280442 | 27813 | 29644054 |
Leukoencephalopathy | 18.75 | 11.09 | 7 | 280604 | 3995 | 29667872 |
Red blood cell count decreased | 18.72 | 11.09 | 157 | 280454 | 26164 | 29645703 |
Hypoglycaemic unconsciousness | 18.66 | 11.09 | 30 | 280581 | 786 | 29671081 |
Pneumonitis | 18.53 | 11.09 | 166 | 280445 | 27288 | 29644579 |
Tenosynovitis | 18.51 | 11.09 | 5 | 280606 | 3510 | 29668357 |
Cytomegalovirus chorioretinitis | 18.48 | 11.09 | 4 | 280607 | 3264 | 29668603 |
Bladder cancer recurrent | 18.45 | 11.09 | 19 | 280592 | 314 | 29671553 |
Glomerular filtration rate increased | 18.42 | 11.09 | 16 | 280595 | 211 | 29671656 |
Birt-Hogg-Dube syndrome | 18.40 | 11.09 | 5 | 280606 | 0 | 29671867 |
Product commingling | 18.34 | 11.09 | 8 | 280603 | 25 | 29671842 |
Angioedema | 18.13 | 11.09 | 436 | 280175 | 33948 | 29637919 |
Abdominal pain upper | 18.01 | 11.09 | 737 | 279874 | 61814 | 29610053 |
Anion gap abnormal | 17.96 | 11.09 | 13 | 280598 | 129 | 29671738 |
Herbal interaction | 17.84 | 11.09 | 19 | 280592 | 327 | 29671540 |
Hyperventilation | 17.82 | 11.09 | 57 | 280554 | 2392 | 29669475 |
Product complaint | 17.81 | 11.09 | 104 | 280507 | 5702 | 29666165 |
Bacteraemia | 17.78 | 11.09 | 80 | 280531 | 15480 | 29656387 |
Erythromelalgia | 17.74 | 11.09 | 9 | 280602 | 43 | 29671824 |
Body mass index increased | 17.71 | 11.09 | 27 | 280584 | 675 | 29671192 |
Needle issue | 17.66 | 11.09 | 77 | 280534 | 3755 | 29668112 |
Aplasia pure red cell | 17.64 | 11.09 | 16 | 280595 | 5610 | 29666257 |
Conjunctivitis | 17.48 | 11.09 | 30 | 280581 | 7970 | 29663897 |
Dizziness | 17.41 | 11.09 | 2083 | 278528 | 192826 | 29479041 |
Lacunar infarction | 17.39 | 11.09 | 67 | 280544 | 3088 | 29668779 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 17.28 | 11.09 | 32 | 280579 | 942 | 29670925 |
Abdominal discomfort | 17.20 | 11.09 | 588 | 280023 | 48203 | 29623664 |
Gastroenteritis | 17.13 | 11.09 | 195 | 280416 | 13071 | 29658796 |
Atrioventricular block complete | 17.13 | 11.09 | 137 | 280474 | 8340 | 29663527 |
Insulin-requiring type 2 diabetes mellitus | 17.10 | 11.09 | 13 | 280598 | 140 | 29671727 |
Therapeutic drug monitoring analysis not performed | 17.04 | 11.09 | 20 | 280591 | 385 | 29671482 |
Cystitis haemorrhagic | 17.03 | 11.09 | 12 | 280599 | 4775 | 29667092 |
Peripheral vascular disorder | 17.00 | 11.09 | 95 | 280516 | 5124 | 29666743 |
Atrioventricular block first degree | 16.87 | 11.09 | 101 | 280510 | 5587 | 29666280 |
Blood ketone body present | 16.81 | 11.09 | 9 | 280602 | 49 | 29671818 |
High density lipoprotein decreased | 16.75 | 11.09 | 67 | 280544 | 3143 | 29668724 |
Neoplasm malignant | 16.73 | 11.09 | 98 | 280513 | 17716 | 29654151 |
Crohn's disease | 16.72 | 11.09 | 10 | 280601 | 4342 | 29667525 |
Erythema | 16.65 | 11.09 | 576 | 280035 | 76875 | 29594992 |
Dysphagia | 16.64 | 11.09 | 404 | 280207 | 56294 | 29615573 |
Torsade de pointes | 16.61 | 11.09 | 26 | 280585 | 7164 | 29664703 |
Bradyarrhythmia | 16.61 | 11.09 | 48 | 280563 | 1904 | 29669963 |
Hyperbilirubinaemia | 16.56 | 11.09 | 92 | 280519 | 16850 | 29655017 |
Hyperdynamic left ventricle | 16.54 | 11.09 | 10 | 280601 | 71 | 29671796 |
Diabetic foetopathy | 16.49 | 11.09 | 15 | 280596 | 211 | 29671656 |
Hyperlipasaemia | 16.48 | 11.09 | 22 | 280589 | 485 | 29671382 |
Coma scale abnormal | 16.46 | 11.09 | 69 | 280542 | 3307 | 29668560 |
Fluid overload | 16.39 | 11.09 | 108 | 280503 | 18984 | 29652883 |
Leukaemoid reaction | 16.35 | 11.09 | 11 | 280600 | 96 | 29671771 |
Nipple inflammation | 16.32 | 11.09 | 10 | 280601 | 73 | 29671794 |
Flushing | 16.31 | 11.09 | 187 | 280424 | 29305 | 29642562 |
Fixed eruption | 16.31 | 11.09 | 35 | 280576 | 1149 | 29670718 |
Neuropathy vitamin B12 deficiency | 16.25 | 11.09 | 7 | 280604 | 21 | 29671846 |
Asthma | 16.10 | 11.09 | 240 | 280371 | 35934 | 29635933 |
Complication associated with device | 15.95 | 11.09 | 18 | 280593 | 5702 | 29666165 |
Hypovolaemic shock | 15.95 | 11.09 | 110 | 280501 | 6390 | 29665477 |
Lithotripsy | 15.93 | 11.09 | 6 | 280605 | 11 | 29671856 |
Plasmapheresis | 15.85 | 11.09 | 18 | 280593 | 334 | 29671533 |
Multiple-drug resistance | 15.84 | 11.09 | 4 | 280607 | 2937 | 29668930 |
Body temperature decreased | 15.83 | 11.09 | 149 | 280462 | 9506 | 29662361 |
Cardiotoxicity | 15.79 | 11.09 | 11 | 280600 | 4403 | 29667464 |
Clear cell renal cell carcinoma | 15.78 | 11.09 | 30 | 280581 | 901 | 29670966 |
Prostatectomy | 15.75 | 11.09 | 13 | 280598 | 159 | 29671708 |
Neonatal respiratory distress syndrome | 15.72 | 11.09 | 9 | 280602 | 4003 | 29667864 |
Hepatojugular reflux | 15.72 | 11.09 | 18 | 280593 | 337 | 29671530 |
Bronchitis | 15.60 | 11.09 | 265 | 280346 | 38860 | 29633007 |
Generalised tonic-clonic seizure | 15.60 | 11.09 | 113 | 280498 | 19438 | 29652429 |
Incorrect route of product administration | 15.59 | 11.09 | 54 | 280557 | 11261 | 29660606 |
Intraductal papillary-mucinous carcinoma of pancreas | 15.50 | 11.09 | 5 | 280606 | 4 | 29671863 |
Colitis ulcerative | 15.44 | 11.09 | 76 | 280535 | 14358 | 29657509 |
Cardiac disorder | 15.41 | 11.09 | 486 | 280125 | 39407 | 29632460 |
Fibrillary glomerulonephritis | 15.32 | 11.09 | 8 | 280603 | 41 | 29671826 |
Sopor | 15.31 | 11.09 | 164 | 280447 | 10827 | 29661040 |
Pseudomembranous colitis | 15.25 | 11.09 | 4 | 280607 | 2864 | 29669003 |
Small intestinal obstruction | 15.15 | 11.09 | 71 | 280540 | 13588 | 29658279 |
Blood alkaline phosphatase increased | 15.04 | 11.09 | 206 | 280405 | 31281 | 29640586 |
Congestive cardiomyopathy | 15.01 | 11.09 | 110 | 280501 | 6517 | 29665350 |
Pulmonary tuberculosis | 15.00 | 11.09 | 14 | 280597 | 4843 | 29667024 |
Weight increased | 14.88 | 11.09 | 851 | 279760 | 74062 | 29597805 |
Lymphoma | 14.84 | 11.09 | 47 | 280564 | 10074 | 29661793 |
Rectal haemorrhage | 14.80 | 11.09 | 234 | 280377 | 34705 | 29637162 |
Bladder papilloma | 14.76 | 11.09 | 7 | 280604 | 28 | 29671839 |
Skinfold measurement | 14.72 | 11.09 | 4 | 280607 | 0 | 29671867 |
Staphylococcal sepsis | 14.68 | 11.09 | 43 | 280568 | 9448 | 29662419 |
Alopecia | 14.62 | 11.09 | 113 | 280498 | 19162 | 29652705 |
Insulin C-peptide decreased | 14.59 | 11.09 | 8 | 280603 | 46 | 29671821 |
Arthropathy | 14.58 | 11.09 | 124 | 280487 | 20603 | 29651264 |
Bradycardia | 14.52 | 11.09 | 752 | 279859 | 64774 | 29607093 |
Folliculitis | 14.50 | 11.09 | 8 | 280603 | 3632 | 29668235 |
Status epilepticus | 14.48 | 11.09 | 54 | 280557 | 11018 | 29660849 |
Virologic failure | 14.47 | 11.09 | 6 | 280605 | 3213 | 29668654 |
Intraductal papillary mucinous neoplasm | 14.44 | 11.09 | 10 | 280601 | 92 | 29671775 |
Leukocytosis | 14.32 | 11.09 | 282 | 280329 | 21220 | 29650647 |
Lung disorder | 14.28 | 11.09 | 208 | 280403 | 31261 | 29640606 |
Expired product administered | 14.27 | 11.09 | 59 | 280552 | 2810 | 29669057 |
Multiple sclerosis relapse | 14.19 | 11.09 | 53 | 280558 | 10809 | 29661058 |
Intercapillary glomerulosclerosis | 14.19 | 11.09 | 8 | 280603 | 49 | 29671818 |
Patent ductus arteriosus | 14.10 | 11.09 | 6 | 280605 | 3163 | 29668704 |
Injection site mass | 14.09 | 11.09 | 87 | 280524 | 4866 | 29667001 |
Pancreatic duct obstruction | 14.09 | 11.09 | 5 | 280606 | 7 | 29671860 |
Scrotal cyst | 14.09 | 11.09 | 5 | 280606 | 7 | 29671860 |
Brain oedema | 14.01 | 11.09 | 64 | 280547 | 12334 | 29659533 |
Akathisia | 13.98 | 11.09 | 21 | 280590 | 5883 | 29665984 |
Urosepsis | 13.97 | 11.09 | 158 | 280453 | 10574 | 29661293 |
Acid base balance abnormal | 13.93 | 11.09 | 6 | 280605 | 18 | 29671849 |
Myasthenic syndrome | 13.91 | 11.09 | 17 | 280594 | 342 | 29671525 |
Aplastic anaemia | 13.91 | 11.09 | 19 | 280592 | 5537 | 29666330 |
Tongue disorder | 13.90 | 11.09 | 12 | 280599 | 4310 | 29667557 |
Heparin-induced thrombocytopenia | 13.89 | 11.09 | 18 | 280593 | 5365 | 29666502 |
Ischaemic stroke | 13.89 | 11.09 | 222 | 280389 | 16053 | 29655814 |
Pneumatosis intestinalis | 13.84 | 11.09 | 4 | 280607 | 2686 | 29669181 |
Eructation | 13.83 | 11.09 | 67 | 280544 | 3417 | 29668450 |
Radiotherapy | 13.82 | 11.09 | 18 | 280593 | 387 | 29671480 |
Mouth haemorrhage | 13.76 | 11.09 | 16 | 280595 | 5001 | 29666866 |
Enthesopathy | 13.75 | 11.09 | 5 | 280606 | 2901 | 29668966 |
Skin lesion | 13.75 | 11.09 | 109 | 280502 | 18385 | 29653482 |
Blood albumin decreased | 13.64 | 11.09 | 66 | 280545 | 12526 | 29659341 |
Blood calcium decreased | 13.60 | 11.09 | 45 | 280566 | 9517 | 29662350 |
Renal artery thrombosis | 13.59 | 11.09 | 16 | 280595 | 309 | 29671558 |
Graft versus host disease in skin | 13.57 | 11.09 | 7 | 280604 | 3300 | 29668567 |
Labelled drug-disease interaction medication error | 13.44 | 11.09 | 10 | 280601 | 104 | 29671763 |
Overweight | 13.42 | 11.09 | 37 | 280574 | 1428 | 29670439 |
Hallucination, visual | 13.40 | 11.09 | 92 | 280519 | 16021 | 29655846 |
Oscillopsia | 13.39 | 11.09 | 7 | 280604 | 36 | 29671831 |
Cytomegalovirus colitis | 13.27 | 11.09 | 3 | 280608 | 2376 | 29669491 |
Product appearance confusion | 13.25 | 11.09 | 6 | 280605 | 21 | 29671846 |
Hypoparathyroidism | 13.25 | 11.09 | 19 | 280592 | 449 | 29671418 |
Kussmaul respiration | 13.20 | 11.09 | 10 | 280601 | 107 | 29671760 |
Thrombosis | 13.20 | 11.09 | 298 | 280313 | 41933 | 29629934 |
Orbital oedema | 13.17 | 11.09 | 11 | 280600 | 137 | 29671730 |
Ascites | 13.15 | 11.09 | 247 | 280364 | 35674 | 29636193 |
Blood cholesterol | 13.13 | 11.09 | 10 | 280601 | 108 | 29671759 |
Oesophageal perforation | 13.09 | 11.09 | 19 | 280592 | 454 | 29671413 |
Pancreatectomy | 13.09 | 11.09 | 7 | 280604 | 38 | 29671829 |
Thyroid cyst | 13.04 | 11.09 | 6 | 280605 | 22 | 29671845 |
Conjunctival disorder | 12.98 | 11.09 | 9 | 280602 | 83 | 29671784 |
Intentional self-injury | 12.94 | 11.09 | 74 | 280537 | 13458 | 29658409 |
Gingival hypertrophy | 12.80 | 11.09 | 39 | 280572 | 1594 | 29670273 |
Eosinophilic colitis | 12.79 | 11.09 | 12 | 280599 | 176 | 29671691 |
Arthropod sting | 12.79 | 11.09 | 14 | 280597 | 249 | 29671618 |
Hypersensitivity | 12.74 | 11.09 | 397 | 280214 | 53631 | 29618236 |
Drug level below therapeutic | 12.74 | 11.09 | 8 | 280603 | 3384 | 29668483 |
Dermatitis acneiform | 12.74 | 11.09 | 21 | 280590 | 5668 | 29666199 |
Metastases to the mediastinum | 12.73 | 11.09 | 12 | 280599 | 177 | 29671690 |
Thrombotic cerebral infarction | 12.73 | 11.09 | 15 | 280596 | 290 | 29671577 |
Thyroxine abnormal | 12.69 | 11.09 | 5 | 280606 | 11 | 29671856 |
Renal tubular disorder | 12.65 | 11.09 | 17 | 280594 | 4989 | 29666878 |
Vascular graft | 12.59 | 11.09 | 36 | 280575 | 1419 | 29670448 |
Bacterial infection | 12.58 | 11.09 | 68 | 280543 | 12542 | 29659325 |
Respiratory syncytial virus infection | 12.58 | 11.09 | 8 | 280603 | 3360 | 29668507 |
Influenza | 12.52 | 11.09 | 310 | 280301 | 43088 | 29628779 |
Wheezing | 12.51 | 11.09 | 209 | 280402 | 30729 | 29641138 |
Benign neoplasm of adrenal gland | 12.51 | 11.09 | 4 | 280607 | 3 | 29671864 |
Hepatobiliary scan abnormal | 12.51 | 11.09 | 4 | 280607 | 3 | 29671864 |
Penile abscess | 12.51 | 11.09 | 4 | 280607 | 3 | 29671864 |
Brain herniation | 12.50 | 11.09 | 10 | 280601 | 3730 | 29668137 |
Blindness cortical | 12.49 | 11.09 | 15 | 280596 | 296 | 29671571 |
Viral infection | 12.48 | 11.09 | 87 | 280524 | 15098 | 29656769 |
Finger amputation | 12.47 | 11.09 | 12 | 280599 | 182 | 29671685 |
Full blood count decreased | 12.46 | 11.09 | 91 | 280520 | 15626 | 29656241 |
Malnutrition | 12.41 | 11.09 | 60 | 280551 | 11389 | 29660478 |
Coma acidotic | 12.39 | 11.09 | 5 | 280606 | 12 | 29671855 |
Klebsiella infection | 12.33 | 11.09 | 29 | 280582 | 6858 | 29665009 |
Explorative laparotomy | 12.28 | 11.09 | 6 | 280605 | 26 | 29671841 |
Limb traumatic amputation | 12.28 | 11.09 | 6 | 280605 | 26 | 29671841 |
Bundle branch block right | 12.21 | 11.09 | 110 | 280501 | 6932 | 29664935 |
Hepatitis B | 12.18 | 11.09 | 24 | 280587 | 6048 | 29665819 |
Vascular resistance systemic decreased | 12.14 | 11.09 | 9 | 280602 | 93 | 29671774 |
Product solubility abnormal | 12.12 | 11.09 | 20 | 280591 | 536 | 29671331 |
Peripheral sensory neuropathy | 12.12 | 11.09 | 23 | 280588 | 5878 | 29665989 |
Blood pressure systolic increased | 12.11 | 11.09 | 204 | 280407 | 14906 | 29656961 |
Myoclonus | 12.09 | 11.09 | 74 | 280537 | 13238 | 29658629 |
Lichenification | 12.08 | 11.09 | 15 | 280596 | 307 | 29671560 |
Nipple disorder | 12.01 | 11.09 | 12 | 280599 | 191 | 29671676 |
Brain stem infarction | 11.98 | 11.09 | 33 | 280578 | 1273 | 29670594 |
Type I hypersensitivity | 11.90 | 11.09 | 27 | 280584 | 921 | 29670946 |
Enteritis | 11.88 | 11.09 | 28 | 280583 | 6617 | 29665250 |
Cellulitis of male external genital organ | 11.78 | 11.09 | 8 | 280603 | 71 | 29671796 |
Muscle spasticity | 11.76 | 11.09 | 19 | 280592 | 5169 | 29666698 |
Neutrophilia | 11.76 | 11.09 | 63 | 280548 | 3344 | 29668523 |
Pulmonary toxicity | 11.76 | 11.09 | 15 | 280596 | 4501 | 29667366 |
Device issue | 11.67 | 11.09 | 36 | 280575 | 7780 | 29664087 |
Inflammation | 11.66 | 11.09 | 141 | 280470 | 21885 | 29649982 |
Post-traumatic amnestic disorder | 11.66 | 11.09 | 7 | 280604 | 49 | 29671818 |
Hemiparaesthesia | 11.66 | 11.09 | 7 | 280604 | 49 | 29671818 |
Subdural hygroma | 11.64 | 11.09 | 15 | 280596 | 319 | 29671548 |
Vertigo | 11.62 | 11.09 | 286 | 280325 | 22349 | 29649518 |
Metabolic syndrome | 11.60 | 11.09 | 36 | 280575 | 1486 | 29670381 |
Carotid artery stenosis | 11.56 | 11.09 | 79 | 280532 | 4575 | 29667292 |
Chronic pigmented purpura | 11.54 | 11.09 | 9 | 280602 | 101 | 29671766 |
Hepatic neoplasm | 11.52 | 11.09 | 41 | 280570 | 1818 | 29670049 |
Sedation | 11.49 | 11.09 | 98 | 280513 | 16275 | 29655592 |
Squamous cell carcinoma of skin | 11.48 | 11.09 | 45 | 280566 | 9050 | 29662817 |
Dyskinesia | 11.47 | 11.09 | 140 | 280471 | 21694 | 29650173 |
Coma uraemic | 11.44 | 11.09 | 7 | 280604 | 51 | 29671816 |
Acute respiratory distress syndrome | 11.41 | 11.09 | 153 | 280458 | 23319 | 29648548 |
Medication error | 11.38 | 11.09 | 267 | 280344 | 20705 | 29651162 |
Alcoholic ketoacidosis | 11.37 | 11.09 | 5 | 280606 | 16 | 29671851 |
Prerenal failure | 11.37 | 11.09 | 41 | 280570 | 1830 | 29670037 |
Hypoosmolar state | 11.34 | 11.09 | 8 | 280603 | 76 | 29671791 |
Polymerase chain reaction | 11.34 | 11.09 | 8 | 280603 | 76 | 29671791 |
Pyonephrosis | 11.34 | 11.09 | 8 | 280603 | 76 | 29671791 |
Cholangiocarcinoma | 11.32 | 11.09 | 27 | 280584 | 952 | 29670915 |
Choluria | 11.32 | 11.09 | 11 | 280600 | 169 | 29671698 |
Lipodystrophy acquired | 11.31 | 11.09 | 10 | 280601 | 3550 | 29668317 |
Hypoaesthesia eye | 11.30 | 11.09 | 6 | 280605 | 32 | 29671835 |
Irritability | 11.29 | 11.09 | 150 | 280461 | 22900 | 29648967 |
Mucormycosis | 11.29 | 11.09 | 20 | 280591 | 5248 | 29666619 |
Venous occlusion | 11.28 | 11.09 | 16 | 280595 | 374 | 29671493 |
Metabolic disorder | 11.28 | 11.09 | 65 | 280546 | 3546 | 29668321 |
Stem cell transplant | 11.28 | 11.09 | 3 | 280608 | 2128 | 29669739 |
Mouth ulceration | 11.27 | 11.09 | 56 | 280555 | 10553 | 29661314 |
Drug ineffective for unapproved indication | 11.23 | 11.09 | 58 | 280553 | 10822 | 29661045 |
Bacterial sepsis | 11.20 | 11.09 | 18 | 280593 | 4908 | 29666959 |
Atrial fibrillation | 11.20 | 11.09 | 1167 | 279444 | 106957 | 29564910 |
Hypogammaglobulinaemia | 11.20 | 11.09 | 20 | 280591 | 5232 | 29666635 |
Toxic nodular goitre | 11.15 | 11.09 | 5 | 280606 | 17 | 29671850 |
Pain in extremity | 11.13 | 11.09 | 885 | 279726 | 109336 | 29562531 |
Lip oedema | 11.12 | 11.09 | 46 | 280565 | 2191 | 29669676 |
Lipase abnormal | 11.11 | 11.09 | 7 | 280604 | 54 | 29671813 |
Splenic varices | 11.11 | 11.09 | 4 | 280607 | 6 | 29671861 |
Base excess negative | 11.11 | 11.09 | 4 | 280607 | 6 | 29671861 |
Foetal malnutrition | 11.11 | 11.09 | 7 | 280604 | 54 | 29671813 |
Dumping syndrome | 11.11 | 11.09 | 4 | 280607 | 6 | 29671861 |
Drug screen positive | 11.10 | 11.09 | 15 | 280596 | 4392 | 29667475 |
Source | Code | Description |
---|---|---|
ATC | A10BA02 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Biguanides |
ATC | A10BD02 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD03 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD05 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD07 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD08 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD10 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD11 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD13 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD14 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD15 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD16 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD17 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD18 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD20 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD22 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD23 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD25 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD26 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
FDA CS | M0002471 | Biguanides |
FDA EPC | N0000175565 | Biguanide |
CHEBI has role | CHEBI:35526 | hypoglycemic drug |
CHEBI has role | CHEBI:35703 | xenobiotic |
CHEBI has role | CHEBI:78298 | environmental contaminants |
MeSH PA | D007004 | Hypoglycemic Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
Treatment Refractory Type 2 Diabetes Mellitus | indication | ||
Gestational diabetes mellitus | off-label use | 11687002 | DOID:11714 |
Polycystic ovaries | off-label use | 69878008 | |
Weight loss | off-label use | 89362005 | |
Polycystic ovary syndrome | off-label use | 237055002 | DOID:11612 |
Prevention of Type 2 Diabetes Mellitus | off-label use | ||
Alcoholism | contraindication | 7200002 | |
Weight gain finding | contraindication | 8943002 | |
Asthenia | contraindication | 13791008 | |
Pulmonary edema | contraindication | 19242006 | DOID:11396 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Acute vomiting | contraindication | 23971007 | |
Severe adrenal insufficiency | contraindication | 24867002 | |
Alcohol intoxication | contraindication | 25702006 | |
Shock | contraindication | 27942005 | |
Dehydration | contraindication | 34095006 | |
Macular retinal edema | contraindication | 37231002 | DOID:4449 |
Infectious disease | contraindication | 40733004 | |
Body fluid retention | contraindication | 43498006 | |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Chronic heart failure | contraindication | 48447003 | |
Lymphocytopenia | contraindication | 48813009 | DOID:614 |
Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
Ketoacidosis | contraindication | 56051008 | |
Acute nephropathy | contraindication | 58574008 | |
Metabolic acidosis | contraindication | 59455009 | |
Hepatic failure | contraindication | 59927004 | |
Hemolytic anemia | contraindication | 61261009 | DOID:583 |
Glucose-6-phosphate dehydrogenase deficiency anemia | contraindication | 62403005 | |
Acute infectious disease | contraindication | 63171007 | |
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Hypopituitarism | contraindication | 74728003 | DOID:9406 |
Cardiogenic shock | contraindication | 89138009 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Fracture of bone | contraindication | 125605004 | |
Liver function tests abnormal | contraindication | 166603001 | |
Cobalamin deficiency | contraindication | 190634004 | |
Angina pectoris | contraindication | 194828000 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Impaired renal function disorder | contraindication | 197663003 | |
Cerebrovascular accident | contraindication | 230690007 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Drug-induced hepatitis | contraindication | 235876009 | |
Hypoglycemic disorder | contraindication | 237630007 | |
Sepsis syndrome | contraindication | 238150007 | |
Edema | contraindication | 267038008 | |
Osteopenia | contraindication | 312894000 | |
Primary adrenocortical insufficiency | contraindication | 373662000 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Fever | contraindication | 386661006 | |
Surgical procedure | contraindication | 387713003 | |
Malignant tumor of urinary bladder | contraindication | 399326009 | DOID:11054 |
Severe diarrhea | contraindication | 409587002 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Traumatic injury | contraindication | 417746004 | |
Fever greater than 100.4 Fahrenheit | contraindication | 426000000 | |
Severe Hypoxemia | contraindication | ||
Prolonged-Severe Nausea and Vomiting | contraindication | ||
Radiography with IV Iodinated Contrast Agent | contraindication | ||
Severe Autonomic Insufficiency | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.63 | Basic |
pKa2 | 3.34 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
1GM;EQ 100MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
2.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Dec. 19, 2022 | NEW CHEMICAL ENTITY |
2.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Dec. 19, 2022 | NEW CHEMICAL ENTITY |
7.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Dec. 19, 2022 | NEW CHEMICAL ENTITY |
7.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Dec. 19, 2022 | NEW CHEMICAL ENTITY |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
1GM;EQ 100MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Dec. 4, 2023 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Dec. 4, 2023 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Dec. 4, 2023 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Dec. 4, 2023 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | June 4, 2024 | PEDIATRIC EXCLUSIVITY |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | June 4, 2024 | PEDIATRIC EXCLUSIVITY |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | June 4, 2024 | PEDIATRIC EXCLUSIVITY |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | June 4, 2024 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mitochondrial complex I (NADH dehydrogenase) | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Dipeptidyl peptidase 4 | Enzyme | IC50 | 4.54 | CHEMBL | |||||
5'-AMP-activated protein kinase subunit beta-1 | Kinase | WOMBAT-PK | |||||||
Solute carrier family 22 member 3 | Transporter | Km | 2.50 | WOMBAT-PK | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 3.40 | WOMBAT-PK | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 2.70 | WOMBAT-PK |
ID | Source |
---|---|
4023979 | VUID |
N0000021984 | NUI |
D00944 | KEGG_DRUG |
1115-70-4 | SECONDARY_CAS_RN |
4020898 | VANDF |
4023979 | VANDF |
C0591573 | UMLSCUI |
CHEBI:6802 | CHEBI |
MF8 | PDB_CHEM_ID |
CHEMBL1703 | ChEMBL_ID |
CHEMBL1431 | ChEMBL_ID |
D008687 | MESH_DESCRIPTOR_UI |
DB00331 | DRUGBANK_ID |
4779 | IUPHAR_LIGAND_ID |
965 | INN_ID |
9100L32L2N | UNII |
14219 | PUBCHEM_CID |
151827 | RXNORM |
41717 | MMSL |
5063 | MMSL |
592 | MMSL |
d03807 | MMSL |
003483 | NDDF |
004534 | NDDF |
109081006 | SNOMEDCT_US |
109083009 | SNOMEDCT_US |
372567009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
JANUMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0078 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 31 sections |
JANUMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0080 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 31 sections |
JANUMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0081 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 31 sections |
JANUMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0575 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 30 sections |
JANUMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0577 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 30 sections |
SEGLUROMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-5369 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 29 sections |
SEGLUROMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-5370 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 29 sections |
SEGLUROMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-5373 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 29 sections |
SEGLUROMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-5374 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 29 sections |
GLUCOPHAGE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0087-6060 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 18 sections |
GLUCOPHAGEXR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0087-6063 | TABLET, EXTENDED RELEASE | 500 mg | ORAL | NDA | 18 sections |
GLUCOPHAGEXR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0087-6064 | TABLET, EXTENDED RELEASE | 750 mg | ORAL | NDA | 18 sections |
GLUCOPHAGE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0087-6070 | TABLET, FILM COATED | 850 mg | ORAL | NDA | 18 sections |
GLUCOPHAGE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0087-6071 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 18 sections |
Glipizide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-7455 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 27 sections |
Glipizide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-7456 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
Glipizide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-7457 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
metformin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-4416 | TABLET, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 28 sections |
Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2751 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 27 sections |
Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2752 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2753 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
KOMBIGLYZEXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6125 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
KOMBIGLYZEXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6135 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
KOMBIGLYZEXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6145 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6225 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6250 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6260 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6270 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6280 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6001 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | ANDA | 29 sections |